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Abstract 
 
Autoimmune Addison’s Disease (AAD) is a classical organ-specific autoimmune disease 
(AID) that is characterized by autoreactivity towards the adrenal cortex, leading to 
insufficient production of steroid hormones and death if left untreated. The genetic factors 
that contribute to AAD development are not well characterized, and it is commonly accepted 
that epigenetic factors are involved in the onset of AAD, as they are for other autoimmune 
diseases. This master project was part of a larger project that aims to identify genomic regions 
that are differentially methylated in AAD patients compared to control individuals through 
the use of methylated DNA immune precipitation in combination with gene array (MeDIP-
chip). DNA methylation is a major epigenetic component that is essential for gene expression 
in embryonic development, normal physiology and disease. Differential methylation status is 
associated with various pathological conditions, such as cancers and autoimmune diseases. 
Therefore, precise mapping of the methylome has become a crucial issue to understand gene 
expression.  
 
The MeDIP-chip approach generated a list of genomic regions that are differentially 
methylated in patients and controls. Some of these regions were analyzed in silico for the 
position in the corresponding gene and to gain insights of the epigenetic properties of the 
specific region. The major part of this thesis work involved the development of methylation 
specific PCR (MSP). This method was developed for the purpose to verify the MeDIP-chip 
data and to allow screening of large cohorts of both AAD patients and other autoimmune 
diseases. MSP protocols, in which different primer sets specifically hybridized with either 
unmethylated or methylated DNA was developed for five genomic regions. Moreover, one 
region was analyzed by bisulphite sequencing. Bisulphite seqeuncing is widely used to 
generate single CpG site methylation maps, but it became evident that it is not suitable for 
methylation analyses of a large quantity of samples. DNA from five patients and five control 
individuals were analyzed with MSP across a region in the FLCN gene that was found to be 
hypermethylated in AAD patients in the MeDIP-chip. Interestingly, this differentially 
methylated region was localized to a CpG-island shore, suggesting regulatory effects of the 
methylation status. The MSP analysis partly verified a different level of methylation in 
patients and controls, but the results strongly suggest that quantitative MSP needs to be 
developed for the genomic regions of interest to be able to distinguish between differences 
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hypo- and hypermethylation. Taken together, the work presented in this master thesis 
contributed to the identification of genomic regions that are differentially methylated in 
patients with AAD and healthy controls, and developed methodology that will be an 
important tool for further evaluation of aberrant methylated regions in patients with 
autoimmune diseases after some further refinement. 
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Introduction 
 
1. Epigenetics and DNA Methylation 
The term “epigenetics” was first used in 1957 by Conrad H Waddington (1905-1975) and 
stated: “Epigenetics is the branch of biology that studies the causal interactions between 
genes and their products, which bring the phenotype into being”. The modern view of 
epigenetics has become narrower, which is now commonly used to refer to heritable traits that 
affect gene expression but that are not caused by the underlying DNA sequence. The 
following definition was posted by Russo in 1996:“The study of mitotically and/or 
meiotically heritable changes in gene function that cannot be explained by changes in DNA 
sequence” (Russo et al.1996). 
 
Epigenetics comprises a variety of modification processes, which can cause long term or short 
term on gene expression programs, and is involved in the regulation of all biological 
processes from conception to death (Handel, Ebers et al. 2010). The major components in 
epigenetics are DNA methylation and histone modification. These modifications can interplay 
with each other and with other mechanisms like non-coding RNAs and regulatory proteins 
(Delcuve, Rastegar et al. 2009).  Histone modifications can be characterized in two different 
ways either by affecting the contact between different histones in adjacent nucleosome or the 
interaction of histones and DNA. Both approaches are affecting chromatin structure. The 
nucleosome is the fundamental unit of chromatin and is composed of a octamer of histones 
wrapped with 147 bp double-stranded DNA (Kouzarides 2007). Histone with DNA wrapped 
tightly regulates genome sequence from abnormal gene expression or modification. Structural 
orchestrations of chromatin are either euchromatin or heterochromatin. Euchromatin is 
characterized by high level of histone acetylation mediated by histone acetyl transferases 
(HATs) and the genes can be actively transcribed. Transcriptional repression is mediated by 
altering of acetylation by the enzyme histone deacetylases (HDACs). The silencing of 
euchromatin converts the chromatin to heterochromatin, which then is enriched by H3 
trimethylation recruited by histone methyltransferase (HMTs). DNA methylation in the 
promoter region of a gene in euchromatin can however block transcription factors association 
with DNA and thereby regulates the initiate of transcription. 
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1.1 DNA Methylation 
DNA methylation is a post-replicative DNA modification where a methyl group is added to 
the 5`position of cytosine (C) residues in the DNA backbone. The reaction is carried out by a 
group of enzymes known as DNA methyltransferases (Dnmts) that uses S-
adenosylmethionine (SAM) as methyl-donor (figure_1). In eukaryotes, DNA-methylation 
occurs almost exclusively at CpG dinucleotides [i.e. where C is followed by a guanine (G) in 
the DNA sequence], although it has been demonstrated that methylation can also occur on C 
followed by A and T, especially in embryonic stem cells (Ramsahoye, Biniszkiewicz et al. 
2000). DNA methylation is common in plants, and in addition to a high frequency of CpG 
methylation, methylation also occurs in CHG and CHH (H is A, C or T) in plants (Zhang, 
Kimatu et al. 2010). In invertebrates, the type and frequency of DNA methylation varies, 
depending on if they have Dnmts or not (Glasted et al. 2011) 
 
 
(Bestor 2000) 
Figure_1: Enzymatic mechanism of DNA methylation. 
 
DNA methylation pattern is inherited because the Dnmt1 is present at the replication fork. 
There are other DNA methyl transferases that carry out de novo methylation including 
Dnmt3a and Dnmt3b. The fact that Dnmt3a and Dnmt3b are also essential for life is proved 
by mouse knockdown studies. Mice that lack of Dnmt3a die within a few weeks after birth 
and different DNA methylation pattern in somatic tissue where non-CpG methylation 
following CpA and CpT is diminished due to low level of Dnmt3a and Dnmt3b (Li, Bestor et 
al. 1992; Okano, Bell et al. 1999).    
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1.2 Biological processes controlled by DNA methylation 
Initial studies demonstrated important roles for DNA methylation in genomic imprinting, X 
chromosome inactivation and heterochromatin maintenance (Bestor 2000). In more recent 
years it has also become evident that waves of demtehylation/remethylation are essential for 
normal embryonic development. These processes are described briefly below:  
 
Genomic imprinting: Genomic imprinting is a process that ensures that a gene is expressed in 
a parent-of–origin specific manner (Robertson 2005). About 100 imprinted genes have been 
characterized in mammals and most of them are identified in clusters (Weaver, Susiarjo et al. 
2009). For instance, human 11p15.5 domain contains a large cluster of imprinted genes, and 
abnormal methylation of some genes within this cluster results in Beckwith-Wiedemann 
syndrome (BWS) (Verona, Mann et al. 2003). DNA methylation is the best characterized 
epigenetic mark involved in the allele-specific expression of imprinted gene, and this 
mechanism is particularly important during paternal sperm development and postnatal oocyte 
maturation (Bartolomei and Ferguson-Smith 2011). Many developmental processes depend 
on that only either the maternal or paternal gene is expressed such as for PEG3 gene. This 
gene is imprinted and thereby not expressed from the maternal allele but expressed from the 
paternal allele. The precise function of PEG3 is not clear but might be involved in p53/c-myc-
mediated apoptosis pathway (Kohda, Asai et al. 2001; Dowdy, Gostout et al. 2005; Feng, 
Marquez et al. 2008). 
 
X-chromosome inactivation: In mammals, males contain one X-chromosome and one Y-
chromosome, whereas female contain X chromosomes. The X-chromosome is gene-rich, and 
many genes are not involved in other processes than sex determination and reproduction. 
Expression of the genes from both X chromosome in the female would cause imbalance of 
gene expression between the sexes and have great impact on metabolic mechanism (Gartler 
and Goldman 2001). Already in 1931, H. J. Muller et al. posted that mammals and some other 
species have evolved a system to bring about the equivalence in expression of X-linked genes 
in females and males. DNA methylation plays a key role in X-chromosome inactivation by 
imposing hypermethylation in promoter regions. Studies in somatic cell hybrids show that 
promoter methylation is one of two critical factors in maintaining silencing on the inactive X 
chromosome. For an instance, promoter hypomethylation in DNMT3B (DNA 
methyltransferase gene) in the inactive X-chromosome results Immunodeficiency,  
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centromeric instability and facial anomalies (ICF) syndrome (Ehrlich, Jackson et al. 2006). It 
is interesting to note, that overall, the inactive X-chromosome is not hypermethylated 
compare to the active one, rather the hypermethylation is targeted to specific regions (Gartler 
and Goldman 2001).     
 
Heterochromatin maintenance: Heterochromatin is defined as highly compacted nuclear 
materials as opposite to the less-condensed euchromatin, and it is believed to be 
hypermethylated. DNA methylation also plays important role in heterochromatin 
maintenance. Both constitutive and facultative heterochromatin is involved in transcriptional 
silencing of genes by DNA methylation along with other functions. Cytosine within 
heterochromatin are highly methylated and, the hypermethylated status act synergistically 
with chromatin modifications to achieve a repressed chromatin stage (figure_2).  
 
 
Figure_2: The role of DNA methylation in heterochromatin maintenance. Heterochromatin is 
inaccessible to transcription due to increased level of cytosine methylation mediated by 
histone methyl transferases (HMTs).  
 
Whole genome studies have revealed interesting roles for DNA methylation in 
heterochromatin orchestration, and demonstrated that heterochromatin is less methylated than 
euchromatin in the highly repetitive juxtacentromeric sequence of the human genome (Suzuki, 
Oda et al. 2011). This might indicate that DNA methylation is linked to chromatin 
organization where less methylation is needed for DNA kept “inaccessible” for transcription 
in heterochromatin and contrapositive for euchromatin.  
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DNA methylation in embryonic development: Diploid zygote formation of gametes during 
fertilization is the primary step of human development, and gametes and later on the zygote 
must go through a reconfiguration configuring all kind of modification. Two phases of global 
demethylation occurs during mammalian development by epigenetic reprogramming 
(figure_3). The first step takes place during germ cell development, which is associated with 
loss of DNA methylation including imprinted genes. The second step takes place after 
fertilization throughout preimplantation period of development, and is also associated with 
loss of DNA methylation excluding imprinted genes. Moreover, paternal and maternal DNA 
shows different pattern of losing DNA methylation just after zygote formation.   
   
 
 
Figure_3: DNA methylation restoration program during embryonic development showing 
stable and inherited pattern of DNA methylation. The diagram depicts the methylation level 
in methylated (black line) imprinted and non-imprinted genes (red; maternal, blue; paternal) 
during germ cell and embryonic development. 
                    (Dean, Santos et al. 2003)  
 
1.3. DNA methylation and regulation of gene transcription 
DNA methylation takes place as major epigenetic modification in respect to ubiquitous and 
tissue specific gene expression. Different transcription factor can bind to hypomethylated 
CpG sites in promoters and initiate transcription. Hypermethylated CpG rich promoters are 
unable to interact with the necessary factors to initiate transcription, and transcription is 
repressed. As described above, there is tight communication of DNA methylation and histone 
modifications, leading to either an open or close chromatin state (Kouzarides 2007). Genomic 
regions of 500-1000 base pairs that contain elevated levels of C and G, and little CpG 
depletion are referred to as CpG-islands (CGI). The total number of CGIs in human genome 
is around 25500 (Illingworth, Gruenewald-Schneider et al. 2010). It is also evident that 
almost half of the CGIs are located in promoters of annotated genes overlapping the 
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transcription start site (Deaton and Bird 2011). CGIs are often found in promoters of 
housekeeping genes and are generally kept hypomethylated, regardless of the transcriptional 
activity of the gene. Around 5% of CGI-promoters exhibit a tissue differentially methylation 
pattern, but the majority of genes that are expressed in a tissue-restricted pattern are 
controlled by promoter containing few CpG sites (also denoted weak CGIs) (Shen, Kondo et 
al. 2007; Irizarry, Ladd-Acosta et al. 2009; Illingworth, Gruenewald-Schneider et al. 2010). 
The roles of CGIs in tissue specific gene expression are emerging and it is now known that 
not all CGIs with a regulatory function are located to promoter area (figure_4). Genome-wide 
analysis reveals their genomic distribution and indicated both intragenic and intergenic 
location. CGIs with no known function are named orphan CGIs, but they might as well be 
important in gene regulation. Another surprising finding through large-scale analysis is that 
many orphan CGIs contain novel promoters (Maunakea, Nagarajan et al. 2010; Deaton and 
Bird 2011).    
 
 
Figure_4: Gene transcription regulation by CGIs. 
  
A. Location of CGIs throughout the human and mouse genome; TSSs, intragenic or 
intergenic. Unmethylated CpG are indicated by empty lollipops and methylated CpG by filled 
lollipops. B. The genomic distribution of CGIs in the human and mouse genome as 
determined in ((Illingworth, Gruenewald-Schneider et al. 2010), figure from (Deaton and 
Bird 2011). 
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1.4. DNA Methylation and disease 
Environmental factors, though epigenetic mechanisms, play important roles in the connection 
between genetic susceptibility and disease development. Life style, food habit and 
environment can promote either hypermethylated or hypomethylated DNA by providing or 
removing methyl groups, which might be the principle reason to develop disease condition 
due to abnormal DNA methylation (table_I).  
 
Table_I: Environmental factors affecting the epigenome 
Environmental factor Evidence for epigenetics 
Methyl donor 
(folate, vitamin B12, 
choline, betadine) 
Sex hormones 
 
 
 
 
Smoking 
 
 
Nutrition 
 
 
Vitamin D 
 
Stress 
Administration to mice causes changes in coat colour mediated by 
altered DNA methylation in region near Agouti gene (Wolff, G.L. et 
al. 1998 & Cooney, C.A. et al. 2002). 
Endocrine toxin causes inheritable defects in DNA methylation-
mediated spermatogenesis in rats (Anway, M.D. et al. 2005). 
Perinatal exposure of human infants to diethylstilbesterol causes 
epigenetic increase in malignancy (Li, S. et al. 2003). 
 
Paternal parent-of-origin transgenerational effects on obesity in 
sons is highly suggestive of epigenetic changes (Pembrey, M.E. et 
al. 2006).  
Parent-of-origin transgenerational effect on mortality in sex-
matched offspring is highly suggestive of epigenetic changes 
(Pembrey, M.E. et al. 2006). 
Vitamin D receptor binding complex can cause epigenetic changes 
(Issa, L.L. et al. 1998). 
Stressful upbringing causes epigenetic changes in glucocorticoid 
receptor promoter region in rats (Weaver, I.C.G. et al. 2004).  
Childhood abuse associated with epigenetic changes in 
glucocorticoid receptor promoter region in human suicide victims 
(McGowan, P.O. et al. 2009). 
This table shows environmental factors that could result in epigenetic changes. 
 
Moreover, unlike genetic changes, which are permanent, autoimmune disease (AID) related 
epigenetic modifications are reversible and this can be potential reason to develop epigenetic 
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therapies to treat complex and polygenic diseases. These changes can also be inherited over 
generation (Ballestar, Esteller et al. 2006). Loss of normal DNA methylation pattern in 
somatic cells results in loss of growth control and hypomethylation and is a hallmark of 
cancer (Robertson 2005). Alternatively, DNA methylation can repress genes, which are 
responsible for disease. ‘Epimutation’, which is abnormal silencing of gene, is the most 
potent example of genetic susceptibility to DNA methylation (Martin, Ward et al. 2005). 
 
2. Autoimmune Addison’s disease 
Autoimmunity develops because of defects in the immune system in which the normal 
process of self-antigen recognition is disturbed. The immune systems start a defence towards 
own cell components because it recognizes self-proteins as foreign molecules. Central 
tolerance is the ability of newly formed T and B cells to recognize but not respond to self-
antigens, and this ensure negative selection. Negative selection is the process, by which high 
affinity T-cells deletion occurs. High affinity T-cells are capable of recognizing self-antigens 
and mount a strong immune response against them. Breakdown of central tolerance is the 
principle explanation of autoimmunity. Autoimmune disorders is third highest burden for 
clinical manifestation in the world (Nossal 2001) and 3-7% of the population in Europe and 
United states are suffering from an autoimmune diseases (Jacobson, Gange et al. 1997; 
Marrack, Kappler et al. 2001). Multiple sclerosis (MS), systemic lupus erythematosus (SLE), 
diabetes mellitus (DM), autoimmune haemolytic anaemia, Rheumatoid arthritis (RA), 
autoimmune Addison’s disease (AAD), autoimmune polyendocrinopathy syndromes (APS) 
are the most common autoimmune diseases.  
 
Addison’s disease (AD) refers to primary adrenocortical insufficiency and is a life- 
threatening disorder first noticed by Thomas Addison in 1885 (T Addison 1855). In most 
cases, AD is caused by autoimmunity and is then referred to as Autoimmune Addison’s 
disease (AAD). AAD is an organ specific autoimmune disease where the target organ is 
adrenal gland (Betterle 2002; Myhre, Undlien et al. 2002; Arlt and Allolio 2003). Adrenal 
cortex destruction occurs by an unknown mechanism and as the disease progresses fibrous 
tissue replaces the cortex. This leads to hampered steroid hormone production and finally 
complete lack of cortical hormone production. The healthy adrenal gland consists of an outer 
cortex and an inner medulla. The cortical portion produces steroid hormones that are essential 
for life, and therefore, if left untreated, AAD is lethal. The cortex consists of three different 
zones; the outer zona glomerulosa that produces mineralo corticoids, the middle zona 
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fasciculata that produces glucocorticoids and inner zona reticularis that produces adrenal 
androgens (figure_5). Aldosterone is the most common and important mineralocorticoid and 
is essential for the regulation of water and salt balance and maintenance of blood pressure. 
Cortisol is the principle glucocorticoid and has profound effects on almost every organ in 
human body including cardiovascular, metabolic, immunologic and homeostatic function 
(Sapolsky, Romero et al. 2000).  
 
 
Figure_5: Microscopic section of Adrenal gland. 
 
The prevalence of AAD and Addison’s disease (AD) in general worldwide is not well 
documented, and most likely many patients are undiagnosed (Ian Ross and Naomi Levitt 
2011). Thereafter, the estimation for autoimmune Addison’s disease is 100-140 per million 
and incidence rates of 5-6 per million (Martina M Erichsen et al. 2009; Delves and Roitt 
2000; Janeway 2001; Medzhitov 2007), while about 90-140 peoples per million are suffering 
in western countries (Ten, New et al. 2001; Lovas and Husebye 2005). The western part of 
Norway has a somewhat higher incidence and the rate is increasing with time (Lovas and 
Husebye 2005). In general, autoimmune diseases are caused by multiple genes dysfunction, 
and most of the autoimmune diseases are coexisted with at least one additional immune 
disorder (Neufeld, Maclaren et al. 1981). For instance, about 50-60% of Addison’s patient 
have at least one additional clinical or preclinical autoimmune disorder like diabetes type I, 
APS I or APS II (Betterle, Lazzarotto et al. 2004) and cardiovascular disease as well (Ian 
Ross and Naomi Levitt 2011). Interestingly, APS type II is defined as AAD in conjunction 
with autoimmune thyroid disease and /or type I diabetes. APS type I is known as autoimmune 
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polyendocrinopathy, candidiasis and ectodermal dystrophy syndrome; APECED. Thus, 
Addison’s patient comorbidity suggests genetic susceptibility of the disease.  
During the 160 years that have passed since the first identification of AD, there have been 
excellent diagnostic advances and a remarkable understanding of the mechanism at the 
molecular level. Hormone replacement therapy has been available from 60 years ago (Ian 
Ross and Naomi Levitt 2011). However, AAD is still a potential lethal condition if 
overlooked, many die due to adrenal failure. The mortality rate is excessively higher in young 
people due to acute adrenal insufficiency, sudden death and most likely because of infection 
(Erichsen, Lovas et al. 2009). The clinical manifestations of AAD patients are non-specific 
and diagnosis can be difficult. Tiredness with muscular weakness is the main reason why 
patients seek medical attention. The two most characteristic symptoms are hyper pigmentation 
and salt craving. The age of diagnosis is usually in forth decade of life (Arlt and Allolio 
2003). An overview of the clinical features of AD patients is given in table_II.   
   
Table_II: Clinical features of Addison’s disease 
Symptoms Signs Biochemical abnormalities 
Fatigue 
 
 
Muscular weakness 
 
Abdominal pain 
 
 
 
Vomiting 
 
Diarrhoea 
Salt craving  
Behavior changes  
Headache, Sweating  
Depression,  
Muscle and pain 
Postural hypotension 
 
 
Weight loss 
 
Generalized pigmentation, 
darkened skin creases, 
pigmented buccal mucosa 
and nail beds 
Associated vitiligo and/or 
goiter 
High (supine) plasma renin and/or 
increased nighttime ACTH levels 
 
Low ACTH stimulated cortisol 
responses 
At the time of crisis: normo-or 
hyponatremia, hyperkalemia, 
hypoglycemia 
Eosinophilia 
 
 
Lymphocytosis 
 
(Ten, New et al. 2001) 
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2.1 Molecular and genetic characteristics of AAD 
It is established that AAD patients have over expression of T-cells and antibody producing B-
cells. The importance of T-cells differentiation in AAD pathogenesis is illustrated by the fact 
that patients present with increased percentage of T-cells along with decreased percentage of 
regulatory T-cells (TREG) (Rabinowe, Jackson et al. 1984; Coles, Thompson et al. 2005). A 
major breakthrough in AAD research was the identification of antibodies against P450 21-
hydroxylase in the majority of AAD patients (Soderbergh, Gustafsson et al. 2006). Adrenal 
antigen specific T cell have been recognised both in adrenal gland and in peripheral blood 
(Nerup, Andersen et al. 1969; Nerup and Bendixen 1969). T-cell response against adrenal 
specific protein fraction and the microsomal fraction as well has demonstrated (Nerup and 
Bendixen 1969; Nerup, Andersen et al. 1970; Ludwig, Eibl et al. 1976; Freeman and 
Weetman 1992). It is not understood why immunoreactivity against P450 21-hydroxylase is 
associated with AAD, besides that this enzyme is essential for steroid hormone production in 
the adrenal cortex (Krohn, Uibo et al. 1992; Winqvist, Gustafsson et al. 1993). 
 
The genetic origin of AAD is not well understood, but has been linked to some genes 
essential for the immune system. The present knowledge indicates that AAD is, as most 
autoimmune diseases, a polygenic disorder. Single nucleotide polymorphism (SNP’s) studies 
from different populations revealed the relation between certain class of HLA haplotype and 
AAD (Maclaren and Riley 1986; Myhre, Undlien et al. 2002; Gombos, Hermann et al. 2007). 
The risk is increased in the presence of the HLA-DRB1*404 allele where one or two single 
amino acid alterations increased antigen peptide presentation by MHC II (Gregersen, Silver et 
al. 1987). MHC class I chain related A (MIC A) has also been linked to the development of 
AAD, as it is involved in up regulation of natural killer cells (NK) and cytotoxic T 
lymphocytes (CTLs) function (Stephens 2001; Spies 2002). CTLA4, CIITA and PTPN22 are 
also genes related to increased risk for AD. All these genes to AD encode proteins that are 
involved in regulation of antigen specific T-cells and they are also associated with other 
autoimmune diseases (Brand, Gough et al. 2005). 
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3. DNA methylation and autoimmunity  
Environmental factors, through epigenetic mechanisms, are believed to contribute to the 
increased prevalence of autoimmune diseases that are observed in industrial societies 
(Veldhoen and Duarte 2010). Only about one-third of the risk of developing an autoimmune 
disease might be caused by genetic factors, and the influence of the environment is evident by 
the discordant penetrance of autoimmune diseases in monozygotic twins (Ballestar 2010). 
The stochastic selection of TCRs is also important as well as non-genetic causes (Gronski, 
Boulter et al. 2004). The best-studied autoimmune diseases with regard to DNA methylation 
are the Silver-Russel and Beckwith-Weidemann syndromes (Verona, Mann et al. 2003). In 
both these syndromes, hypomethylation is observed. Several studies have focused on the 
importance of the DNMTs and how they might be involved in autoimmunity (Meda, Folci et 
al. 2011). DNMT-activity is impaired in B and T-cells in SLE patients (Brooks, Le Dantec et 
al. 2010).  
 
In the immune system, several pathways that play major roles in lymphocyte proliferation and 
differentiation are regulated by DNA methylation (Adam E. Handel et al. 2009). For instance, 
CD40L, which is Cluster of Differentiation 40 (glycoprotein), is overexpressed in women 
with SLE and manifest a demethylation of the corresponding gene on the inactivated X-
chromosome (Meda, Folci et al. 2011). Hypomethylation of the TNFSF7 promoter causes 
over activation of CD4+ T-cells followed by B-cells activation and autoantibody production 
with subsequent organ damage in SLE patient (Zhou, Qiu et al. 2011). Although DNA 
methylation has been demonstrated to be involved in other autoimmune disease, and play 
important roles in T-cell biology and differentiation, it has not been investigated with regard 
to AAD before. 
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Aims of the Study 
 
The work presented in this master thesis was the part of a project where the major aim is to 
identify genomic regions that are differentially methylated in patients with AAD. MeDIP-chip 
analyses identified genomic regions that were either hypo- or hypermethylated compared to 
controls. These regions where situated most frequently in CpG-islands, but were also found in 
CpG-island shores, gene promoters, introns, exons and in intergenic regions. 
 
The specific aims were: 
1) Contribute to the MeDIP-chip by preparing DNA and MeDiP of control samples. 
2) Characterize in silico a selected number of genetic regions identified in the MeDIP-chip 
with regard to genetic location (as specified above), and examine the existing literature to 
identify potential links to autoimmunity or the immune system.  
3) Establish a protocol of methylation specific PCR (MSP) for a selected number of genomic 
regions. 
4) Establish bisulphite sequencing (BSP) for a selected number of genomic regions. 
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Materials 
 
1. Oligonucleotides applied in PCR as primers 
Table_III: PCR primers used for MSP 
Gene & Primer Sense primer (5'--3') Antisense primer (5'--3') Size, bp 
 
FLCN, M 
FLCN, U 
 
HDAC4, M 
HDAC4, U 
 
SLC30A10, M 
SLC30A10, U 
 
GRIN2B, M 
GRIN2B, U 
 
RCC2, M 
RCC2, U 
 
 
GTCGTGTTTTGGTAATAGTTTC 
GGTTGTGTTTTGGTAATAGTTTT 
 
GTTTATGAGATTTTGTCGGC 
TGGTTTATGAGATTTTGTTGGT 
 
CGAAGATTTTGAAGGGGAAC 
TAGTGAAGATTTTGAAGGGGAAT 
 
ATAAATACGGCGTGGTTAGC 
GATAAATATGGTGTGGTTAGT 
 
AGTGTTTTGGTGCGGAATC 
AGTGTTTTGGTGTGGAATT 
 
ATTACAAACGTAAACCACTACG 
AATTACAAACATAAACCACTACA 
 
ACGATAACTCCAACGAACTC 
AAACAATAACTCCAACAAACTC 
 
CGTAAAATATAACCTCATCCGC 
CATAAAATATAACCTCATCCACCAC 
 
CCGAATACACGCCTACCTA 
ACCAAATACACACCTACCTA 
 
CGACCTAAACAACACAACGAA 
CAACCTAAACAACACAACAAA 
 
181 
181 
 
112 
112 
 
170 
170 
 
170 
170 
 
121 
121 
M represents methylated-specific primers and U, unmethylated-specific primers. 
 
Table_IV: Primers used in nested PCR 
Gene & Primer Sense primer (5'--3') Antisense primer (5'--3') Size, bp 
 
FoxP3, O 
FoxP3, N 
 
AGTGGGATGTACCCAGCTAC 
GGCCCCATTGGAGGAGAT 
 
 
 
ATAGAGCTTCAGATTCTCTTTCTTT 
TCAGATGACTCGTAAAGGG 
 
 
 
652 
360 
 
O represents- primers for outer region and N, nested primers. 
 
Table_V: Primers used in sequencing 
Identification 
Name 
Direction Target Region Sequence 
 
201 
 
 
R 
 
SP6 (pGEM) 
 
GGAAACAGCTATGACCATGATTA 
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2. Bacterial strain used and medium 
Table_VI: E.Coli strain 
Bacterial Strain Provider Genotype 
 
DH5α 
 
 
Stratagene, USA 
F- endA1 glnV44 thi-1 recA1 relA1 gyrA96 deoR 
nupG Φ80dlacZΔM15 Δ(lacZYA-argF)U169, 
hsdR17(rK- mK+),λ– 
 
Table_VII: Bacteria growth medium 
Medium for Ampicillin Selection Contents 
 
 
LB- medium 
Bacto- Tryptone (10%), Difco BD, USA 
Bacto-Yeast Extract (5%), Difco BD, USA 
NaCl (0.17 M), Merck, Germany 
Ampicillin (100 µg/ml), Sigma, USA 
 
LB-plates 
LB-medium 
Agar (15%) provided by BIO-RAD Laboratories Inc., 
USA 
 
 
 
3. Chemicals, molecular biology reagents and kits 
Table_VIII: Modifying enzymes 
Name Supplier 
GoTaq® Flexi DNA Polymerase 
T4 DNA ligase 
Promega, USA 
Promega, USA 
 
Table_IX: Plasmid 
Name Insert Provider 
 
pGEM 
 
Amplified bisulphite 
treated fragment 
 
 
Promega, USA 
 
Table_X: Molecular weight standards 
Name Supplier 
 
100 bp DNA Ladder 
 
1 kb DNA Ladder  
 
 
New England Biolabs, USA 
 
New England Biolabs, USA 
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Table_XI: Chemicals and supplementary 
Chemical and Reagents Supplier 
Molecular Biology Agarose 
 
Bromophenol Blue (0.042% bromophenol blue, 
0.042% xylene cyanol FF, 2.5% Ficol 400) 
 
Ampicillin and Ethidium Bromide 
 
Bacto-Yeast extract 
 
X-Gal 
 
Isopropyl β-D-1-thiogalactopyranoside (IPTG) 
 
Ethanol 
 
Iso-propanol 
 
TAE buffer (40 mM Tris, 0.1% Acetic acid, 1 
mM EDTA (pH 8.0)) 
BIO-RAD Laboratories Inc., USA 
 
Merck, Germany 
 
Sigma, USA 
 
Difco BD, USA 
 
Promega, USA 
 
Promega, USA 
 
Arcus, Norway 
 
Arcus, Norway 
 
Prepared in the Lab 
 
 
Table_XII: Molecular biology kits 
Name Supplier Catalogue No.  
DynalCD4 Positive Isolation Kit 
 
MagMeDIP Kits (48xTM) 
 
DNeasy blood and tissue kit (250) 
 
IPure DNA Isolation Kit (250)  
 
GenomePlex Complete Whole Genome  
Amplification (WGA) Kit 
 
E.Z.N.A Plasmid Mini Kit (250 preps) 
 
QIAquick Gel Extraction Kit 
 
QIAquick PCR Purification Kit (250) 
 
MinElute® PCR Purification kit (250) 
 
EZ DNA Methylation-Gold kitTM 
Invitrogen, USA 
 
Diagenode, Belgium 
 
Qiagen, USA 
 
Diagenode, Belgium 
 
Sigma, USA 
 
 
Omega Bio-Tek, USA 
 
Qiagen, USA 
 
Qiagen, USA 
 
Qiagen, USA 
 
Zymo Research, USA 
113.31D 
 
mc-Magme-048 
 
69506 
 
AL-100-0100 
 
070M6184 
 
 
D 6942-02 
 
28706 
 
28106 
 
28006 
 
D5006 
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4. Technical instruments 
Table_XIII: Equipments 
Instrument Use Manufacturer 
BioRad Gene Pulser II 
 
MJ Research PTC-200 
 
Innova 4430 
 
NanoDrop 
Spectrophotometer 
 
Bioruptor 
 
BIO-RAD iCycler 
 
Transluminator 
 
Incubator (Termaks)  
Electroporation 
 
PCR 
 
Bacterial Shaker 
 
DNA Concentration 
Measurement 
 
Sonication 
 
Quantitative PCR 
 
UV Transmitter  
 
Incubator 
BIO-RAD Laboratories Inc., USA 
BIO-RAD Laboratories Inc., USA 
New Brunswick Scientific, USA 
Thermo Scientific, USA 
 
 
Diagenode, Belgium 
 
BIO-RAD Laboratories Inc., USA 
Fujifilm, Japan 
 
Thermo LAB, India 
 
 
 
5. Computer software 
Table_XIV: Software utilities 
Software 
Specification 
Developer 
Clustal X 2.0.10 
 
BioEdit 7.0.9.0 
 
Methyl Primer 
Express 
 
Reverse 
Complement 
Software  
 
Adobe 
Illustrator CS4 
Alignment of Sequence 
 
Visualization of 
chromatograms 
Primer Design 
 
 
Make DNA 
Complimentary 
 
 
Sequence Editing 
Software 
Conway Institute UCD Dublin, Ireland  
 
Ibis Therapeutic, USA 
 
Applied Biosystems, USA 
 
 
http://www.geneinfinity.org/sms/sms_reversec
omplement.html 
 
 
 
M Microsoft Incorporation, USA 
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Methods 
 
1. Patients 
The patient DNA used in this study was obtained from a Norwegian bio-bank and registry on 
patients with Addison’s disease, directed by Dr. Husebye, Dept of Medicine, Haukeland 
University Hospital, Bergen, Norway. The control DNA was obtained from healthy blood 
donors via the blood bank of Haukeland Hospital. 10 patients with confirmed AAD was 
analyzed in the MeDiP-chip (Human DNA Methylation 2.1M Deluxe Promoter Array, 
NimbleGen Roche, Inc.). Informed consent had been obtained by Dr. Husebye for genetic 
studies, and the Regional Committee for Ethics in Medical Research (REK149/96) had 
approved the investigation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Methods 
 21 
2. Methylation specific polymerase chain reaction 
MSP is probably the most sensitive non-quantitative method due to its capability to detect 
0.1% methylation or less at any block of CpG sites (Rand, Qu et al. 2002; Kristensen, 
Mikeska et al. 2008). The method is outlined in figure_6(A and B) is essential that the 
primers that recognize methylated DNA. The unique characteristic of methylated primer pair 
facilitate to distinguish methylated DNA sequence in a background of unmethylated DNA, 
and the unmethylated primer pair only amplify the unmethylated DNA. 
 
Figure_6A: Principle of methylation specific PCR (MSP) for methylated DNA. 
 
 
Figure_6B: Principle of methylation specific PCR (MSP) for methylated DNA. 
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3. Positive isolation of CD4+ T-Cells from blood  
Dynal® CD4 positive isolation kit was used to isolate CD4+ T-cells from blood from patients 
and controls. This kit is based on a primary monoclonal antibody specific for the CD4 
membrane antigen. Whole blood was washed with buffer 1 (PBS, with 0.1% BSA and 2mM 
EDTA but without Ca2+ and Mg2+, pH 7.4) to remove interfering soluble factors present in the 
plasma fraction. Dynabeads CD4 are uniform magnetic polystyrene bead coated with CD4+ 
T-cells specific primary antibody that will capture the CD4+ T-cells. Before use, the 
Dynabeads were prepared by washing with buffer 1. The ration between Dynabeads and 
washed whole blood was 5x106 Dynabeads to 1 ml of blood. The isolated CD4+ T-cells were 
then washed three times with buffer 1 and resuspended in 100 µl Buffer 2 (RPMI 1640/1% 
FCS)/ml blood. 
 
DETACHaBEAD was used to detach the bead from the CD4+ T-cells. DETACHaBEAD 
CD4 is a polyclonal anti-Fab antibody specific for the CD4 primary antibody and is supplied 
with the kit. Detached beads were removed from the sample with additional wash steps with 
buffer 2 and a magnet. Isolated CD4+ T-cells were then transferred in Buffer 2 (500 µl) and 
cell number was determined by counting in a Bürker chamber. 
 
3.1. Purification of DNA from isolated CD4+ T-cells  
DNA from isolated CD4+ T-cells was purified by using the Qiagen DNeasy Blood & Tissue 
Kit. Cells (maximum 5 x 106) were first incubated with adequate amount of proteinase K and 
RNase A (100 mg/ml) at room temperature for 2 min. Protienase K is a serine protease that 
digests the proteins including nucleases, and therefore protects nucleic acid from degradation. 
RNase A catalyses the degradation of RNA and thus removes RNA from the sample. The 
cells where then lysed in buffer AL and incubated in this lysis buffer for 30 min at 58°C. 70% 
ethanol was added, and the samples were applied to silica-based membrane columns that bind 
DNA to remove contaminants and enzyme inhibitors. The columns were washed with buffer 
AW1 and buffer AW2. The DNA was then eluted in elution buffer (200 µl). The 
concentration of the purified DNA was determined by a NanoDrop fluorospectrophotometer. 
The purified DNA was stored at 4°C.  
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4. Immunoprecipitation of methylated DNA (MeDIP)  
The Diagnode MagMeDIP kit was used to immunoprecipitate (IP) methylated DNA. The 
method is a genome-wide, high-resolution approach to detect and isolate methylated DNA. 
Enriched methylated DNA can be interrogated using DNA microarray. Purified DNA (10 µg) 
was dissolved in elution buffer (200 µl) and sonicated to produce fragments of 300-500 bp. 
The sonication intervals were 15 seconds ‘ON’ and 15 seconds ‘OFF’ for 15 minutes.  To 
verify that the DNA was shared, the sonicated DNA (0.1 µg in 1x DNA loading dye; 0.007% 
bromophenol blue, 0.007% xylene cyanol FF, 0.42% Ficol 400) was analyzed by agarose gel 
electrophoresis (1%) in 1x TAE buffer. The sonicated DNA was prepared for IP with a buffer 
supplied with the kit, and control DNA and the anti-methylcytosine antibody used to 
precipitate methylated DNA was diluted to 1:2 with water according to manufacturer’s 
instructions.  
 
Before IP, the DNA was denatured at 95°C, to allow for binding of the antibodies, and 
quickly chilled on ice. 10% of this sample was separated for input and kept at 4°C before 
further downstream preparation. The washed and prepared Magbeads capable to bind the 
antibody and the antibody mixture was then added and the reaction was incubated overnight 
on a rotating wheel at 4°C. The next morning, the IP reactions were washed three times with 
ice-cold MagWash buffer-1 (100 µl; detergent, salt anion chelator mix incubated) in a cold 
room. Each wash consisted of resuspension by inverting the tubes, incubation for 4 minutes at 
4°C on a rotating wheel (40 rpm), collection of the beads by centrifugation and incubation in 
the magnetic rack for 1 minute before the buffer was discarded. The detergent mix in the 
MagWash buffer-1 helps to dissolve nuclear membranes around the DNA and the salt mixture 
denatured any remaining DNase. The captured beads were kept attached to the tube wall. The 
beads were washed again with ice-cold MagWash buffer-2 (100 µl; detergent, salt anion 
chelator mix) by following the procedure stated above, and the beads were kept on ice. 
 
4.1. Purification of MeDIP DNA 
The MeDIP isolated DNA was purified and eluted from the antibody-beads by the Diagnode 
IPure kit. This kit is commonly used to purify DNA for downstream application like 
hybridization to microarray. Elution buffer (1:1 mix of buffers A and B provided by the kit) 
were added to the bead pellet (50 µl) and the input sample (92.5 µl elution buffer to 7.5 µl 
input sample) and incubated for 15 minutes at RT on a rotating wheel (40 rpm). The samples 
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were centrifuged briefly in a microfuge and placed into the DiaMag2 magnetic rack for 1 
minute. The methylated DNA containing supernatant was collected into new tubes and the 
elution was repeated once. Iso-propanol (100 µl) and a carrier able to bind DNA and the 
magnetic beads was added to each IP reaction and input sample together with magnetic beads 
(15 µl) and incubated for 1 hour at RT on a rotating wheel (40 rpm). The bead-bound DNA 
was then washed with wash buffer 1 and wash buffer 2 according with a short incubation (1 
minute) at room temperature on a rotating wheel (40 rpm). The DNA was eluted in buffer C 
(supplied with kit) in a total of 50 µl (two elusions, each 25 µl). The concentration of eluted 
DNA was measured by UV fluorospectrophotometry (NanoDrop). Magnetic beads were kept 
in liquid suspension at 4°C at all times, as drying will result in reduced performance.  
 
5. Whole genome amplification 
As hybridization to NimbleGen Human DNA Methylation 2.1M Deluxe Promoter Array 
required 6 µg of DNA, the MeDIP-DNA was amplified by the GenomePlex® Complete 
Whole Genome kit. According to the manufacturer, this kit amplifies the entire genomic DNA 
with minimum amplification bias. The starting amount of DNA is critical, and according to 
the kit, 10 ng is optimal. When using a complex starting material, such as human genomic 
DNA, the gene bias in the resulting GenomePlex product is significantly altered if the 
quantity of input DNA is reduced. The first step in the GenomePlex® Complete Whole 
Genome kit is to convert the immunoprecipitated fragments into PCR-amplifiable units 
flanked by universal adaptor sequences. These modified fragments (that together makes up 
the OmniPlex library) are then subjected to a limited number of PCR cycles to produce 
enough material hybridization to the array. The procedure was followed according to the 
manufacturer’s recommendation. In short, 10 ng of DNA was used for each amplification. 
Fragmentation buffer provided by the kit (1 µl) was added to the DNA (10 ng) followed by 
denaturation at 95°C for 4 minutes.  
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The OmniPlex library DNA was then generated by using the library preparation enzyme (1µl) 
and library solution buffer (2 µl) in the stepped isothermal reactions as follows below:  
Table_XV: The OmniPlex library generation isothermal cycles 
Temperature (°C) Incubation time (min) 
16°C 20 minutes 
24°C 20 minutes 
37°C 20 minutes 
75°C 5 minutes 
4°C Hold 
 
Amplification accompanied by following the cycle below: 
Table_XVI: The profile of thermocycling in amplification 
Steps Temperature Incubation time Cycles 
Initial Denaturation 95°C 3 minutes × 1 
Denaturation 
Anneal/Extension 
94°C  
65°C 
15 seconds 
5 minutes 
× 14 
 
The final WGA DNA was stored at - 20°C and is as stable as any genomic DNA sample. 
 
5.1. Purification of WGA DNA 
The amplified DNA contains primers, nucleotides, polymerases and salts that must be 
removed before DNA array hybridization. The Qiagen MinElute PCR Purification kit 
performed this. Five volumes of binding buffer PB was mixed with one volume of PCR 
reaction and transferred onto MinElute column following centrifugation (13000xg) for one 
minute. Column bound DNA was then washed with wash buffer (750 µl) and centrifuged for 
one minute. One additional one-minute centrifugation was carried out to remove residual 
ethanol from wash buffer. Double-distilled water (10 µl) was applied directly to the column 
matrix and left for one minute before centrifugation to elute the DNA.  
 
6. Quantitative real time PCR 
To verify the immunoprecipitation and amplification of methylated DNA, quantitative PCR 
(qPCR) on known methylated and unmethylated region was performed. qPCR was used 
because this method can determine the concentration of a certain transcript in the sample. 
qPCR is based on detection of a fluorescent signal produced proportionally during the 
amplification of a PCR product.  
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qPCR of isolated DNA was carried out by using the iCycler software where isolated DNA (10 
µl) was applied with primer pair (reverse and forward) by following the qPCR cycle below: 
Table_XVII: The delineation of temperature cycle during qPCR reaction 
Steps Temperature Incubation time Cycles 
95°C 7 minutes ×1 
95°C 15 seconds 
60°C 60 seconds 
×40 
 
 
Amplification 
95°C 1 minute ×1 
 
Melting curve 
65°C and 
increment of 
0.5°C per cycle 
1 minute ×60 
 
 
7. Microarray analysis 
Microarray technology has become one of the most powerful tools for biological research and 
also widely used in methylation analysis because of its high throughput manner. DNA 
methylation microarrays are specialized microarray technology used to measure provided 
DNA methylation by hybridizing with probes attached to a solid surface. Each probe contains 
a specific DNA sequence corresponding this project; the Human DNA Methylation 2.1 M 
Deluxe Promoter Array from NimbleGen Roche was used. This array covers CpG-islands and 
promoters. This array requires around 6 µg of input DNA, with an optimal concentration of 
250-500 µg/µl. The WGA DNA was sent to NimbleGen (Reykjavik, Iceland) for 
hybridization. The raw microarray data was processed and analyzed by Dr. Bettina 
Andreassen at the department of Biostatistics, University of Oslo. An overview of the MeDIP 
procedure followed by WGA and microarray is shown in appendix I. 
 
8. Bisulphite conversion 
DNA methylation detection is essential for the study of epigenetic changes in the genome. 
Several methods have been developed to analysis DNA methylation, and methods applying 
bisulphite conversion are the most commonly used techniques. This is accomplished by 
temperature denaturation to replace chemical denaturation with sodium hydroxide, which 
causes unmethylated cytosine to be converted into uracil while methylated cytosine remain 
unchanged. The amount of DNA per treatment can range from 500 pg to 2 µg and an optimal 
amount is 200-500 ng regarding the instruction given EZ DNA Methylation-Gold Kit. The 
purified genomic DNA (500 ng) of CD4+ T-cells was treated with sodium bisulphite salt (130 
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µl; dissolved in M-dissolving buffer and M-dilution buffer, provided by the kit). The 
conversion was performed in a thermal cycler following the conditions below: 
Table_XVIII: The denaturation temperature cycles for bisulphite treatment  
Step Temperature (°C) Incubation time 
98°C 10 minutes 
64°C 2.5 hours 
 
Denaturation 
4°C Storage up to 20 hours 
  
The purification of converted DNA was achieved by using Zymo-spin IC silica membrane 
column together with M-binding buffer (600 µl). M-binding buffer bind the DNA to the 
column and the column was washed once with washing buffer containing absolute ethanol 
(100 µl) before desulphonation in M-desulphonation buffer (200 µl) provided by the kit. The 
desulphonation step prevents precipitation of bulky DNA. The DNA was washed again to 
stop the desulphonation reaction and eluted by spinning briefly after a short incubation with 
elution buffer provided by the kit (10 µl). It is important to minimize template degradation 
and loss of DNA during treatment and cleanup, and this was assured by thoroughly following 
the procedures given by the manufacturer’s recommendation. The DNA was then ready for 
immediate analysis of nested PCR followed by cloning and sequencing or MSP. 
 
9. Methylation specific PCR (MSP) 
The amplification mix was prepared (1.25 unit of DNA Polymerase enzyme, 1 mM MgCl2, 1x 
buffer (yellow dye), 10 mM dNTP, 20 mM forward primer and 20 mM reverse primer) and 
added with 100 ng DNA sample in a 25 µl PCR reaction. The following PCR settings were as 
shown in table_XIX: 
Table_XIX: The profiles of isothermal cycles in Methylation specific PCR 
Step Temperature (°C) Incubation time Number of cycles 
 
Initiation 
 
 
95°C 
 
 
5 minutes  
 
 
 
 
Denaturation 
Annealing 
Elongation 
 
 
95°C 
55-60°C 
72°C 
 
30 seconds 
30 seconds 
30 seconds 
 
 
35 cycles 
 
Final extension 
End 
 
 
72°C 
4°C 
 
4 minutes 
Forever 
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The fragments amplified by MSP were analyzed by agarose gel electrophoresis as described 
below. 
 
10. Nested bisulphite PCR (biPCR) 
Nested bisulphite PCR (biPCR) is often used when bisulphite treated single stranded DNA is 
the template because this template is fragile. According to the principle of nested PCR, the 
use of two primer sets will highly increase the specificity of the amplification. For the second 
round, amplified DNA from the first round was used as DNA template with the same settings. 
The application mix contained 100 ng of DNA in a 25 µl PCR reaction (1.25 unit of DNA 
Polymerase enzyme, 1 mM MgCl2, 1x buffer (yellow dye), 10 mM dNTP, 10 mM forward 
primer and 10 mM reverse primer). The settings were as shown in table_XX. 
Table_XX: The profiles of isothermal cycles in bisulphite PCR 
Step Temperature (°C) Incubation time Number of cycles 
 
Initiation 
Denaturation 
Annealing 
Elongation 
 
 
96°C 
96°C 
57.4°C 
72°C 
 
2 minutes 30 seconds 
45 seconds 
1 minute 30 seconds 
2 minutes 
 
 
 
5 cycles 
 
Denaturation 
Annealing 
Elongation 
Final extension 
End 
 
 
95°C 
57.4°C 
72°C 
72°C 
4°C 
 
30 seconds 
1 minute 30 seconds 
1 minute 30 seconds 
10 minutes 
Forever 
 
 
 
30 cycles 
 
 
11. Agarose gel electrophoresis 
Agarose gel electrophoresis is a method used to separate DNA according to size. The method 
is frequently used after PCR to visualize and isolate the amplified fragments. DNA separation 
occurs by applying an electricity field to the gel. The negatively charged DNA molecules 
migrate towards the positive cathode. The fragments were visualized on 2.5% agarose gels 
prepared in 1xTAE buffer. To visualize DNA in a transluminator, ethidium bromide (10 µl) 
was added. Ethidium bromide becomes interchalated into the DNA strand, and works as 
fluorescent tag under UV-light. A 100 bp ladder was used as the molecular weight marker.  
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12. Gel extracted DNA purification and cloning 
Gel extraction of the fragments amplified in the nested PCR was carried out to purify the 
fragments for downstream applications. Excised gel pieces (150-200 mg) was dissolved in 
QG buffer supplied with the QIAquick Gel Extraction Kit by 10 minutes at 57°C incubation 
and vortexing every second minute. QG buffer is a solubilization and binding buffer with pH 
indicator, which can confirm the pH and efficient for absorption of the DNA to the QIAquick 
membranes remaining yellow. The DNA is washed with the ethanol containing wash buffer 
PE and eluted by applying elution buffer (40 µl; 10mM Tris-Cl, pH 8.5). Elution efficiency is 
dependent on pH and the maximum elution efficiency is achieved between pH 7.0 to 8.0. The 
DNA fragments (6.5 µl) of interest were ligated into the pGEM vector in the presence of 
DNA ligase enzyme (2 µl) following incubation for half an hour in room temperature. After 
desalting by using cellulose membrane for 15 minutes at room temperature. Desalting was 
performed because salt can reduce the transformation efficiency.  
 
12.1. Transformation of E.coli 
Transformation into DH5α strain of E.Coli was performed by both heat-shock at 42°C and 
electroporation. Because of the hydrophobic bilayer core, DNA never passively diffuses 
across the cell membrane. The heat shock opens the pores of the bacterial cell wall and the 
plasmids can enter the cell. Placing the cells on ice after the heat shock closes the pores. The 
commercially available One®TOP10 chemically competent E.coli strain was used for heat-
shock transformation. The bacteria and the pGEM vector containing the amplified fragment 
of interest was kept on ice before and after the heat shock. Desalted ligation reaction (20 µl) 
was transferred into One Shot® cells (50 µl) by mixing gently by tapping the tube. The 
mixture was incubated in ice for 5 min before incubation at 42°C for 30 sec, and then placed 
immediately on ice for 2 minutes. The sample was resuspended in pre-warmed S.O.C. 
medium (250 µl) and incubated at 37°C for 1 hour with shaking at 225 rpm.  
 
Electroporation makes nm-scale water-filled holes in the bacterial cell wall by applying 
electric charge. The lipid molecules of membrane shift position, opening up a pore as a 
conductive pathway and allow the plasmid to enter the cell. After removing the charge, the 
pore close automatically. The electro competent strain of E.Coli (DH5α) was thawed on ice. 
Desalted ligation mix (20 µl) was mixed with bacteria (40 µl) by tapping the tube, and the 
reaction was transferred to a cuvette. Electroporation was carried out at 200 Ohms, 25 mF, 1.8 
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kV. The bacteria was resuspended in LB medium (1 ml) immediately and transferred to a 15 
ml Falcon tube and incubated for 1 hour at 37°C in a shaking incubator at 225 rpm. 
 
12.2. Blue-White screening 
Blue-white screening is a method to identify bacterial clones that contain plasmids with 
successful ligation of the fragment of interest into the vector. After ligation and 
transformation the transformed bacteria are grown in the presence of X-gal. If the ligation is 
successful, the colony will be white because the reading frame of the LacZ gene is disrupted. 
Blue colonies are due to the presence of IPTG (Isopropyl-β-D-1-thiogalactopyranoside) in the 
growing substrate. The transformed bacterial cultures (100 µl or 200 µl) were plated onto LB 
plates containing ampicillin (100µg/ml), X-gal (80 µg/ml) and IPTG (80 µg/ml). For the 
pUC19 control, the transformation mix was diluted 1:10 into LB Medium (e.g. 100 µl of the 
transformation mix with 900 µl of LB Medium) before plating. The plates were incubated at 
37°C for 17 hours.  
 
12.3. Plasmid extraction 
Successfully transformed single bacterial colonies were picked from selection plates and 
inoculated to in 5 ml LB medium containing ampicillin (100µg/ml) in 15 ml Falcon tubes for 
14-20 hours at 37°C with vigorous shaking at 225rpm. Plasmids were isolated from 
inoculated cultures by using the E.Z.N.A® Plasmid Mini Kit. The bacteria were pelleted by 
centrifugation at 10000xg for one minute at room temperature and resuspended in solution I 
containing RNase A provided with the kit (250 µl). Solution-I contains glucose, Tris, and 
EDTA. Glucose is added to increase the osmotic pressure outside the cells. Tris is a buffering 
agent used to maintain a constant pH (8.0). EDTA protects the DNA from DNase; EDTA 
binds divalent cations that are necessary for DNase activity whereas RNase A is used to make 
RNA free solution. Complete resuspension (no visible cell clumps) of cell pellet is vital for 
obtaining good yields. Solution-II provided by the kit (250 µl) was then added and the 
samples were mixed gently by inverting and rotating tube to obtain a clear lysate. Vigorous 
mixing should be avoided because it can cause chromosomal shearing and potential 
contamination of genomic DNA and lower plasmid purity. Solution-II contains NaOH and 
SDS (a detergent). The alkaline mixture ruptures the cells, and the detergent breaks apart the 
lipid membrane and solubilizes cellular proteins. NaOH also denatures the DNA into single 
strands. 
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Next solution-III (350 µl), also provided by the kit, was added and the sample mixed by 
inverting several times until white precipitation was formed. It is vital that the solution is 
mixed thoroughly and immediately after the addition of solution III to avoid uneven 
precipitation. Solution-III contains a mixture of acetic acid and potassium acetate. The acetic 
acid neutralizes the pH, allowing the DNA strands to renature. The potassium acetate 
precipitates SDS from the solution, along with cellular debris. The E. coli chromosomal DNA 
is also trapped in the precipitate but the plasmid DNA remains in solution. The fractionation 
step following centrifugation for 10 minutes at 13000xg is carried out to separate the plasmid 
DNA from the cellular debris and chromosomal DNA in the pellet. The supernatant is added 
in an equilibrated HiBind DNA Mini Column. The plasmid DNA was then washed using 
DNA wash buffer (700 µl) and eluted by adding of MQ water (40 µl) after 1 min incubation. 
The plasmid concentration was determined with a NanoDrop fluorospectrophotometer. 
 
13. DNA sequencing 
The purified plasmids were sequenced using the BigDye kit to verify that the inserts were 
correct. The reaction mix contained DNA template (200 ng), reverse primer 201 (4 pmol), Big 
Dye (1 µl), sequencing buffer (µl) and H2O to a total volume of 10 ml pursuing the 
sequencing set-up listed in Table_XXI. The plasmids were sequenced at the sequencing 
facility, SeqLab, at the University of Bergen. The sequencing data was analyzed by the 
ClustalX and BioEdit software to profile the DNA methylation in the target segment. 
Table_XXI: Sequencing set-up for BSP sequencing 
Step Temperature (°C) Incubation time Number of cycles 
Initiation 
Denaturation 
Annealing 
Elongation 
End 
95°C 
96°C 
58°C/48°C* 
56°C 
4°C 
3 minutes 
14 seconds 
14 seconds 
3 minutes 
Forever 
 
 
 
35 cycles 
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 Results 
 
The major aim of this thesis was to develop methyl specific PCR (MSP) for specific genomic 
regions that were identified as differently methylated in patients with AAD compared to 
control individuals. The regions were identified by applying the MeDIP methodology in 
combination with gene array (Human DNA Methylation 2.1M deluxe promoter arrays from 
NimbleGen Roche, Inc). Preparation of genomic DNA from CD4+ T-cells and the MeDIP 
experiments were mainly performed by PhD-candidate Trine Bjånesøy, but I contributed to 
the procedure by preparing the samples from some control individuals. The different 
preparation and verification methods performed are described on page under “Methods”, but 
the results from the intermediate steps from the DNA isolation and MeDIP are not shown 
here. Dr. Bettina Kulle Andreassen at University of Oslo performed the statistical analysis of 
the array data. The list of the differentially methylated regions that were identified is shown in 
appendix II. It is important to note that this list is based on the number of probes on the array 
that hybridize to a specific genomic region, meaning that the larger the genomic region that is 
differentially methylated between patients and controls, the better score this region will 
obtain. Moreover, all genomic regions listed in appendix II were found to be differently 
methylated in all patients and all controls. The MeDIP-chip data is based on array data from 
10 AAD patients and 12 control blood donors. 
 
However, before the data was processed by Dr. Andreassen, I analyzed a specific region in 
the promoter of the FoxP3 gene based on the data generated by NimbleGen. Both patients and 
control had DNA methylation in promoter sequence, but patient showed substantial more 
methylation in all patients compared to all controls. This region was analyzed by BSP as 
described below. 
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BSP analysis of the FoxP3 
The gene encoding FoxP3 (FoxP3) was analyzed by nested PCR followed by bisulphate 
sequencing. FoxP3 is a transcription factor coding for Forkhead box protein P3 with key 
regulating function in the development of regulatory T-cells (Wang, de Zoeten et al. 2009). 
The gene contains 12 exones, and is located on the negative strand of the X-chromosome, 
according to UCSC genome browser (http://genome.ucsc.edu/). For all genes, NCBI/hg18, 
March-2006 assembly was used to localize the gene positions. It has been demonstrated that 
the DNA methylation status of the proximal promoter of FoxP3 is associated with its 
expression (Li, Zhao et al. 2011). The region that was identified as hypermethylated in 
patients compared to controls is localized within the proximal promoter region around the 
transcription start site, as indicated in figure_7A. The identified region contains 14 CpG sites, 
but do not form a CGI according to the definition of Gardiner-Garden and Frommer 
(Gardiner-Garden and Frommer 1987). The setting were; length > 200 bp, GC content > 50%, 
the ratio of observed CpG/ expected CpG > 0.60. The outer BSP primers were designed as 
outlined in figure_7B. The nested primers amplified a region covering ten CpG sites 
(figure_7C). No significant difference in DNA methylation between two AAD patients and 
two controls individuals was found (figure_7D-H).  
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Figure_7: BSP analysis of FoxP3. 
 
A: Schematic presentation of the FoxP3 gene with exons 1-12 indicated by coloured red bars. 
Associated promoter region have indicate by green bar. The gene is 13.88 kb long; spanning from 
position 49,008,232 to 48,994,354 on the X-chromosome. The transcriptional start site is marked by a 
broken arrow and the region found to be hypermethylated according to preliminary result from the 
MeDIP-chip is indicated by bordering with red lines from 49,008,233 bp to 49,007,534 bp. B: The 
region identified is highlighted and vertical lines indicate the CpG sites. Primers for first round PCR 
are indicated in B and the target region for nested primers bordered with black lines. C: The BSP-
amplified sequence region is highlighted and the sequence and the name of primers are indicated; 
indicated primers binding sites (upper case) with covered CpG sites. D-G: Electrphoretic mobility 
analysis chart showing the result of the bisulphite sequencing analysis on DNA from two AAD 
patients and two control individuals. Each vertical line with circles represents one analysed clones, 
and each circle one CpG site (10 CpG sites). Black circles illustrate methylated CpG sites and white 
circles unmethylated CpG sites. H: The results in D-G are presented as percentage methylated with 
unmethylated as well. The bars represent the average of clones as mean +/– SD (n for P-1; 13, P-2; 7, 
C-1; 16, C-2; 13). 
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The reason for developing MSP for selected genes was that we wanted an efficient tool to 
verify the regions identified through the MeDIP-chip approach, and to be able to screen more 
patients, also from other cohorts. In short, the procedure was as follows:  
 
1) Genomic regions from the array data was selected based on the known association to 
autoimmune diseases or because the nature of the differentially methylated region.  
2) The selected genomic regions were analyzed in silico by the software UCSC genome 
browser (http://genome.ucsc.edu/) to determine if the region contained promoters, enhancers, 
CpG sites or CpG-islands. 
3) By use of the Methyl Primer Express software, primers were designed that would 
recognized either methylated or unmethylated DNA after bisulfite conversion. Primers that 
recognized unmetylated DNA are hereafter called ‘unmethylated primers’ and primers that 
recognized methylated DNA called ‘methylated primers’. 
4) PCR experiments were performed on completely methylated or unmethylated human DNA 
to verify their specificities. 
5) The primer set developed for the gene encoding folliculin was tested on AAD patients and 
control individuals.  
 
Primer design for Methylation Specific PCR (MSP) 
The purpose of MSP is to determine the difference in methylation status focusing on a 
sequence of a specific genomic region in individuals in the case and control group. The 
applied primers must discriminate between methylated and unmethylated cytosine after 
bisulfite conversion so that the methylated primer pairs hybridize only to the methylated 
DNA, and unmethylated primer sets only to unmethylated DNA. Depending on the CpG 
content of the region of interest, primer design can be challenging. The Methyl Primer 
Express software was used to design the MSP primers. In this software CGIs are identified 
according to the definition of Gardiner-Garden and Frommer (Gardiner-Garden and Frommer 
1987); length > 200 bp, GC content > 50%, the ratio of observed CpG/ expected CpG > 0.60. 
The selected sequence that is used as input is modified in silico to mimic bisulfite modified 
DNA. It is important to take into account that the two strands will not be complimentary after 
bisulfite conversion. Methylated primers must cover a minimum of two CpG sites, and to get 
a more robust binding to the template, one CpG site should be located at the most 3’-end of 
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the primer. Unmethylated primers must cover the same CpG sites as the corresponding 
methylated primers. See table_III page 16 for primer sequences. 
 
Preparation of unmethylated control DNA  
The methylated control human DNA was purchased from New England Biolabs, USA. To 
prepare the unmethylated control DNA for MSP, genomic DNA was isolated from blood of a 
healthy donor. The DNA was subjected to fragmentation and amplified. Methylation is lost 
during whole genome amplification (WGA). Five reactions were run in parallel, and the 
quality of the WGA DNA was controlled by gel electrophoresis before purification. As shown 
in figure_8, all samples consisted of a smear in the range of 200-800 bp, with the mean size ~ 
400 bp, which was requirement for downstream application. Importantly, this is the same 
range as control DNA (control in the most right lane), which was provided with kit.  
 
 
 
Figure_8: Agarose gel electrophoresis (1.5 %) of WGA DNA. 10% of the reactions were 
applied to the gel. Sample 1-5: 5 reactions of WGA were run in parallel Control; amplified 
DNA. A bp ladder (100 bp ladder from New England Biolabs, USA) was use to indicate size. 
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Presentation of methylation status between patients and controls by comparing results 
obtained from microarray (example from the FLCN)  
 
Processing of the Human DNA Methylation 2.1M Deluxe Promoter array data generated 
results that could be visualized in the software SingleMap provided by NimbleGen Roche, 
Inc. Signal Map enables us to visualize data organized into panes and tracks, and thereby 
identify peak correlations between our data and annotated tracks like transcription start sites 
and CpG-islands. Analysis with SingleMap was performed on many of the identified regions, 
and to provide an example, the panels in figure_9 show the methylation differences between 
one patient and one control across a selected region of the FLCN gene. In the upper panel, 
nucleotide position on chromosome 17 is indicated by 1000 bp intervals. The next panel 
shows the annotated data for CpG-islands in this part of the FLCN gene. The green bar below 
indicates a CpG-island that is located around 17,065,700. In the middle and lower panel, the 
pink lines show the number of hits in the array hybridization for the patient and blue lines 
show the number of hits for the control. The area found differentially methylated between 
patients and controls after biostatistical calculations are marked with a red box. From this 
figure we can see that there is a clear difference in hits in the selected region between one 
patient and one control, and thus a difference in methylation status. It also shows us that this 
area is located in vicinity of a CpG-island, in a so-called CpG-island shore (Irizarry, Ladd-
Acosta et al. 2009). As the methylation status of CpG-island shores is strongly related to gene 
expression, the region is potentially very interesting. The drawback when it comes to 
SignalMap as a tool to analyze the data provided from NimbleGen Roche, is that it is not 
possible to compare all patients and controls simultaneously, and therefore not possible to 
calculate the statistical difference in methylation of the patients and control as groups. The 
CpG-island is situated in the region from 17,065,424 to 17,065,656. This correlates with the 
data from the UCSC genome browser.  
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Figure_9: Statistical analysis of DNA methylation status for the genomic region 
corresponding to FLCN gene by using the Human DNA Methylation 2.1M Deluxe Promoter 
array and visualized in the software SignalMap supplied by NimbleGen Roche, Inc. The 
numbers on top indicate the base pair position of the FLCN gene on chromosome 17 
(http://genome.ucsc.edu/). The CGI in exon-8 is shown in green in the upper panel. In middle 
and lower panel, the pink and blue vertical lines illustrate the number of hits in the array 
hybridization, for patients and controls, respectively. The region highlighted by the red box 
(1434 bp, from position 17,067,730 to 17,066,296) was differentially methylated in all 
patients and all controls.  
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Functional assessment of MSP primers for FLCN 
 
An intragenic region in the FLCN gene (FLCN) was found to be hypermethylated in all AAD 
patients compared to controls. The FLCN encodes folliculin, a protein known as a co-player 
in apoptosis and down regulates the immune response. Moreover, the finding that the 
differently methylated region was localized to a CpG-island shore, made this as interesting 
region to analyse further. The FLCN contains 14 exons, and is located on the negative strand 
of chromosome 17, which is in the Smith-Magenis syndrome region (location: 17p11.2). 
Exons 4 to 14 contain the coding sequence and exons 1 to 3 are non-coding (figure_10A). 
According to the UCSC genome browser (http://genome.ucsc.edu/), FLCN contains two 
CGIs; one is located in 640 bp downstream of the region that was hypermethylated in patients 
(CpGI-2; 17,065,424 to 17,065,656 bp, 233 bp long) and the other is located to the promoter 
region of the gene (CpGI-1; 17,080,843 to 17,081,805, 963 bp long)(figure_10A). For all 
genes analysed, CpG-islands were predicted by searching the sequence one base at a time, 
scoring each dinucleotide (+17 for CG and -1 for others) to get maximally scoring segments, 
which are then evaluated with the definition of Gardiner-Garden, 1987 (Gardiner-Garden and 
Frommer 1987). 
   
Interestingly, the region that was identified as hypermethylated in patients compared to 
controls in the MeDIP-chip, is located within 640 bp upstream of the CGI in exon 7 (indicated 
by grey bars in figure_10A). CpG rich regions that are located in the vicinity of a CGI are 
referred to as a ‘shores’. CGI shores are known to be particularly dynamic with regard to 
methylation status and are often modified in disease (Irizarry, Ladd-Acosta et al. 2009). The 
identified region contains 34 CpG sites, but do not form a CGI according to the settings stated 
above. MSP primers were designed as outlined in figure_10C, covering six CpG sites in the 
amplicon. As shown in figure_10D, the methylated primers specifically amplified a product 
of 181 bp when methylated DNA was used as template, whereas the unmethylated primers 
only produce a product from unmethylated DNA (figure_10E). This result demonstrates that 
these primer sets designed for the FLCN gene specifically hybridize to fully methylated or 
unmethylated DNA. 
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Figure_10: MSP primer pair screening for FLCN. 
 
A: Schematic presentation of the FLCN where exons 1-14 indicated by red bars. The gene is 24.97 kb 
long; spanning from position 17,081,227 to 17,056,254 on chromosome 17. The identified CGI is 
indicated by a grey bar. The promoter is indicated by transcription start side (TSS) and located 
between position 17,081,995 and 17,080,614. TSS is indicated by a broken arrow; the region 
identified as hypermethylated in AAD patients (spanning from nucleotide position 17,067,730 to 
17,066,296) is indicated by bordering with red lines in A, and highlighted with each CpG site 
illustrated by a vertical line in B. C: The MSP-amplified region is highlighted with the amplified 
sequence and indicated primers binding sites (upper case) with covered CpG sites shown. D, E: 
Agarose gel electrophoresis (2.5%) of PCR products (181 bp) generated by methylated primers (D) 
and unmethylated primers (E). A 100 bp ladder (New England Biolabs, USA) was use to indicate size. 
Results 
 41 
Functional assessment of MSP primers for SLC30A10 
 
The promoter region of the gene encoding SLC30A10 (solute carrier family 30 member 10) 
was hypermethylated in AAD patients. SLC30A10 is a Zn-transporter that has been 
associated with the development of autoimmune Parkinson’s disease (Hamza, Zabetian et al. 
2010). The gene contains 4 exons, and is located on the negative strand of chromosome 1 
(location: 1q41). Exon 3 and 4 are coding sequence whereas exons 1 to 2 are non-coding 
(figure_11A). According to the UCSC genome browser (http://genome.ucsc.edu/), the 
SLC30A10 contains one CGI; covering the gene regulatory region and non-coding first exon 
completely. 
 
Interestingly, the similarly to FLCN, the region identified as hypermethylated in patients in 
SLC30A10, is also located a putative CGI shore (within 175 bp upstream of the CGI) 
(figure_11A). The identified region contains 15 CpG sites, but do not form a CGI according 
to the settings stated above (figure_11C). MSP primers were designed as outlined in 
figure_11C, covering seven CpG sites in the amplicon. As shown in figure_11D, the 
methylated primers specifically amplified a product of 170 bp when methylated DNA was 
used as template, whereas the unmethylated primers only produce a product from 
unmethylated DNA (figure_11E). This result demonstrates that these primer sets designed for 
the SLC30A10 specifically hybridize to fully methylated or demethylated DNA. 
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Figure_11: MSP primer pair screening for SLC30A10. 
 
A: Schematic presentation of SLC30A10 with exons 1-4 indicated by red bars. The gene is 15.15 kb; 
and located at position 218,168,616 to 218,154,222 on chromosome 1. The transcription start site is 
indicated by a broken arrow and the identified CGI by a grey bar. The region identified as 
hypermethylated in AAD patients (spanning from nucleotide position 218,169,494 to 218,168,945) is 
located 329 bp upstream of first exon and is indicated by bordering with red lines in A. This region is 
highlighted with each CpG site illustrated by a vertical line in B. C: The MSP-amplified region is 
highlighted with the amplified sequence and indicated primers binding sites (upper case) with covered 
CpG sites shown. D, E: Agarose gel electrophoresis (2.5%) of PCR products (170 bp) generated by 
methylated primers (D) and unmethylated primers (E). A 100 bp ladder (New England Biolabs, USA) 
was use to indicate size. 
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 Functional assessment of MSP primers for HDAC4 
 
An intragenic region was found to be hypermethylated in the gene encoding histone 
deacetylase 4 (HDAC4) in AAD patients compared to controls. As the name indicates, 
HDAC4 deacetylates histones, which generally leads to a closed chromatin structure and 
transcriptional repression. However, the major reason for analysing this gene further was the 
well-established association of HDACs in autoimmunity (Brooks, Le Dantec et al. 2010).  
The gene contains 27 exons, and is located to the negative strand of chromosome 2 (location: 
2q37.3). Exons 2 to 27 are coding sequence and exon 1 is non-coding (figure_12A). 
According to the UCSC genome browser (http://genome.ucsc.edu/), the HDAC4 contains 
fifteen CGIs. 
  
The region that was identified as hypermethylated in patients is located in intron/exon as 1-
2/2 (figure_12A) and therefore interesting since first exon is potentially important for 
transcription initiation. The identified region contains 45 CpG sites (figure_12B), but 
although the CpG site density is high it is not defined as a CGI according to the settings stated 
above. MSP primers were designed as outlined in figure_12C, covering eight CpG sites in the 
amplicon. As shown in figure_12D, the methylated primers specifically amplified a product 
of 112 bp when methylated DNA was used as template, whereas the unmethylated primers 
only produce a product from unmethylated DNA (figure_12E). This result demonstrates that 
these primer sets designed for the HDAC4 gene specifically hybridize to fully methylated or 
unmethylated DNA. 
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Figure_12: MSP primer pair screening for HDAC4. 
 
A: Schematic presentation of the HDAC4 gene with exons 1-27 indicated by red bars. The gene is 
352.78 kb and located at position 239,987,580 to 239,634,801 on chromosome 2. Regulatory region 
featured from 239,988,808 bp to 239,987,567 bp. The transcriptional start site is indicated by a broken 
arrow. The region identified as hypermethylated in AAD patients (spanning from nucleotide position 
239,941,071 to 239,938,602) is indicated by bordering with red lines in A. This region is highlighted 
with each CpG site illustrated by a vertical line in B. C: The MSP-amplified region is highlighted with 
the amplified sequence and indicated primers binding sites (upper case) with covered CpG sites 
shown. D, E: Agarose gel electrophoresis (2.5%) of PCR products generated (112 bp) by methylated 
primers (D) and unmethylated primers (E). A 100 bp ladder (New England Biolabs, USA) was use to 
indicate size. 
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Functional assessment of MSP primers for RCC2 
 
An intragenic region in the gene encoding regulator of chromosome condensation 2 (RCC2) 
was found to be hypermethylated in patients with AAD compared to controls. RCC2 protein 
is required in normal cell division and has not been associated with autoimmunity but the 
abnormal methylation pattern identified with MeDIP-chip was highly methylated in patients 
compare to control. The fact that this gene harbours three CGIs ensured me to go further with 
MSP analysis. The gene contains 13 exons and is located to the negative strand of 
chromosome 1 (location: 1p36.13). Exons 2 to 13 are known as protein coding exons and 
exon 1 is non-coding (figure_13A). According to the UCSC genome browser 
(http://genome.ucsc.edu/), the gene contains three CGIs.  
 
The region identified as hypermethylated in patients compared to controls is located in exon 
8-11 (figure_13A). The identified region contains 45 CpG sites (figure_13B) but do not form 
a CGI according to the settings stated above. MSP primers were designed as outlined in 
figure_13C, covering six CpG sites in the amplicon. As shown in figure_13D, the methylated 
primers specifically amplify a product of 121 bp when methylated DNA was used as 
template, whereas the unmethylated primers produce a product of the same size from 
unmethylated DNA (figure_13E). For both methylated and unmethylated DNA, an unspecific 
band appeared with the unmethylated (figure_13E). This is the reason of unmethylated 
primers trends to bind unspecifically. This result demonstrates that these primer sets designed 
for the RCC2 gene specifically hybridize to fully methylated or unmethylated DNA.  
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Figure_13: MSP primer pair screening for RCC2. 
 
A: Schematic presentation of the RCC2 gene with exons 1-13 indicated by red bars. The gene is 52.94 
kb, spanning nucleotide position 17,638,807 to 17,605,866 on chromosome 1. The promoter is located 
at 17,639,023 to 17,638,675. The transcriptional start site is indicated by a broken arrow. The region 
identified as hypermethylated in AAD patients (spanning nucleotide position 17,610,713 to 
17,613,311) is indicated by bordering with red lines in A. This region is highlighted with each CpG 
site illustrated by a vertical line in B. C: The MSP-amplified region is highlighted with the amplified 
sequence and indicated primers binding sites (upper case) with covered CpG sites shown. D, E: 
Agarose gel electrophoresis (2.5%) of PCR products generated (121 bp) by methylated primers (D) 
and unmethylated primers (E). A 100 bp ladder (New England Biolabs, USA) was use to indicate size. 
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Functional assessment of MSP primers for GRIN2B 
 
A region localized to an intronic CGI in the gene encoding N-methyl-D-aspartate receptor 
subunit 2B (GRIN2B) was found to be hypermethylated in AAD patients compared to 
controls. GRIN2B is important for memory and learning processing, and is associated with 
autoimmune schizophrenia disorder responses (Carter 2011).  GRIN2B contains 13 exons, and 
is located to the negative strand of chromosome 12 (location: 12p13.1). All exons contain 
coding sequence (figure_14A). According to the UCSC genome browser 
(http://genome.ucsc.edu/), the GRIN2B gene contains one CGI; located in exon 13 (spanning 
nucleotide position 13,608,301 to 13,607,117; 1185 bp long) (figure_14A). 
 
Interestingly, the region that was identified as hypermethylated in patients compared to 
controls in the MeDIP-chip, is located within a CGI in exon 13 (figure_14A). The majority of 
CGIs are kept unmethylated, and only around 5 % of CGIs are differentially methylated. The 
identified region contains 58 CpG sites and this is a CGI according to the settings stated 
above (figure_14C). MSP primers were designed as outlined in figure_14C, covering thirteen 
CpG sites in the amplicon. As shown in figure_14D, the methylated primers specifically 
amplified a product of 170 bp when methylated DNA was used as template, whereas the 
unmethylated primers only produce a product from unmethylated DNA (figure_14E). This 
result demonstrates that these primer sets designed for the GRIN2B gene specifically 
hybridize to fully methylated or unmethylated DNA. 
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Figure_14: MSP primer pair screening for GRIN2B. 
 
A: Schematic presentation of the GRIN2B gene with exons 1-13 indicated by red bars. The gene is 
located to chromosome 12, spans 418.91 kb (nucleotide positions 14,024,319 to 13,605,411). The 
transcriptional start site is indicated by a broken arrow. The region identified as hypermethylated in 
AAD patients (spanning nucleotide position 13,608,267 bp to 13,607,348 bp) is indicated by bordering 
red lines in A. This region is highlighted with each CpG site illustrated by a vertical line in B. C: The 
MSP-amplified sequence region is highlighted with the amplified sequence and indicated primers 
binding sites (upper case) with covered CpG sites shown. D, E: Agarose gel electrophoresis (2.5%) of 
PCR products generated (170 bp) by methylated primers (D) and unmethylated primers (E). A 100 bp 
ladder (New England Biolabs, USA) was use to indicate size. 
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MSP to analyse the methylation status of the FLCN in AAD patients and controls 
 
As shown in figure_10, the MSP primers discriminated between fully methylated or 
unmethylated DNA across the region of the FLCN gene that was identified as 
hypermethylated in AAD patients compared to controls in the MeDIP-chip dataset. To 
investigate whether the difference in methylation status would be evident with MSP, DNA 
from five patients (figure_15A-B) and five controls (figure_15C-D) where analyzed with 
MSP. Importantly, these patients and controls were also included in the MeDIP-chip. As 
expected, the methylated and unmethylated primers only amplified product from the 
methylated and unmethylated controls, respectively, but the unmethylated primers were less 
efficient than the methylated primers (figure_15). The methylated primers amplified 
efficiently the right product from patient DNA (figure_15A) and although MSP-products with 
methylated primers were also evident in the control samples (figure_15C), these bands were 
relatively weaker than in the patients. It is difficult to interpret the results obtained with the 
unmethylated primers due to the low levels of amplicon. But the difference is visible 
(figure_15B-D) where at least one control (C-4 in figure_15D) is presenting a very week band 
along with the unmethylated control DNA. It is although clearly demonstrated that MSP on 
DNA from patients did not generate product with unmethylated primers (figure_15B). This 
finding is therefore in accordance with the MeDIP-chip results, namely that this region is 
hypermethylated in patients.   
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Figure_15: Methylation status of the differentially methylated region identified in the FLCN. 
 
Agarose gel electrophoresis (2.5%) on MSP products obtained with methylated (A and C) and 
unmethylated primers (B and D) on DNA isolated from AAD patients (A and B) or control individuals 
(C and D). P1 to P5 are samples from patients and C1 to C5 are samples from control donors. 
Methylated Control DNA; fully methylated DNA, Unmethylated Control DNA; WGA amplified 
(unmethylated DNA), blank; no DNA. A 100 bp ladder (New England Biolabs, USA) was used as size 
marker. 
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Discussion 
 
DNA methylation affects approximately 1% of DNA bases in the human genome and is a 
major epigenetic modification in respect to tissue specific gene expression (Hughes and Jones 
2007). It is today well recognized that generally, hypermethylation leads to gene silencing and 
hypomethylation to gene expression. Thus, DNA methylation might be viewed as a 
controlling system for gene expression that acts independently of alternations in the DNA 
sequence (Umetani, de Maat et al. 2005).  Since DNA methylation is reversible, there is great 
therapeutic interest in the process. Moreover, it is therefore also immense interest in the basic 
mechanisms of DNA methylation and how it contributes to diseases development. Complex 
diseases like cancer and autoimmune disorder are mostly polygenic, and it is also commonly 
believed that epigenetic mechanisms contribute as well. DNA hypermethylation, and in some 
cases hypomethylation, are found in some forms of cancer and autoimmune disorders (Fraga, 
Ballestar et al. 2005; Handel, Ebers et al. 2010; Meda, Folci et al. 2011). The human 
epigenome project is ongoing to map genome-wide the DNA methylation patterns of all 
human genes in all major tissues (http://www.epigenome.org) and will eventually provide an 
invaluable tool to understand the role of DNA methylation in embryonic development, 
physiology and disease. DNA methylation plays a regulative role in the genome rather than 
the only initiating gene silencing (Weber and Schubeler 2007). This is a dynamic feature 
where the gene expression pattern of a cell depends upon its methylation profile (Paulsen and 
Ferguson-Smith 2001). Overall, only around 4-8% of CGIs exhibit tissue specific methylation 
(Shen, Kondo et al. 2007; Irizarry, Ladd-Acosta et al. 2009; Illingworth, Gruenewald-
Schneider et al. 2010). The remaining CGIs are found throughout genes associated with exons 
(coding and non-coding) and introns where they might also be important for gene expression 
by producing defective protein. DNA methylation and demethylation in the genome is 
established as a model for inhibition of cryptic initiation, protection against mobile elements 
and maintenance of genome stability (Weber and Schubeler 2007). Aberrant DNA 
methylation can lead to chromosomal instability which can cause mutation in gene thereby 
affect gene expression (Paulsen and Ferguson-Smith 2001).  
 
 
 
 
Discussion 
 52 
Autoimmune diseases comprise a large group of systemic and organ specific disorders that 
together constitute a major cause of illness and death. Autoimmune diseases are typically 
manifested by abnormal differentiation of different subtypes of CD4+ T-cells (e.g. regulatory 
T-cells; TREG, IL-17-producing T helper cells; Th17 and IL-22 producing T helper cells; 
Th22) followed by abnormal production of interleukins (Buckner 2010). The incidence ratio 
for autoimmune disease is strikingly higher in females, with a prevalence as high as 10:1 
(Invernizzi, Pasini et al. 2009). Surprisingly, the frequency of autoimmune Addison’s disease 
is higher in young people and predominantly in female within the age of 20-60 years. In the 
study that this thesis is a part of, the choice of patient group was female in the range of 
between 20-60 years due to the fact that most patients in the Norwegian Addison’s Disease 
cohort are this group with in as the risk probability showed in statistics indicate (Erichsen, 
Lovas et al. 2009). Although DNA methylation has not previously been studied in an AAD 
cohort, it is established that epigenetic abnormalities are associated with autoimmune 
diseases. This is exemplified by studies demonstrating that changes in genome-wide T-cell 
DNA methylation is associated with various autoimmune diseases, and they suggest that 
changes in DNA methylation causes aberrant gene expression leading to loss of tolerance in 
CD4+T-cells (Jeffries, Dozmorov et al. 2011). This study shows that the difference between 
patients with autoimmune disease and healthy controls in respect to DNA methylation is cell 
type specific. The difference is cell type specific primarily in CD4+ T-cells for AAD. Other 
studies exemplified in regulatory T-cells and B cells for SLE (Jeffries, Dozmorov et al. 2011); 
lymphocytes and synovial fibroblast for RA (Rodrigues, Jungel et al. 2009); and lymphocytes 
and skin fibroblast for the patient with systemic sclerosis. Examples of organ specific 
autoimmune disease are type 1 diabetes, multiple sclerosis (MS), idiopathic 
thrombocytopenic purpura (ITP) and celiac disease (Brooks, Le Dantec et al. 2010).  
 
Epigenetic regulation of immune regulatory genes is demonstrated in several studies. FoxP3 
is a forkhead family transcription factor expressed and required for development of CD4+ 
regulatory T-cells, therefore, involved in autoimmune reaction (Polansky, Kretschmer et al. 
2008). Mutations of FoxP3 lead to deficiency of regulatory T-cells and development of 
autoimmunity appear most likely due to lack of negative selection (Floess, Freyer et al. 2007). 
Moreover, the expression of FoxP3 is methylation sensitive and the proximal promoter 
methylation status revealed the significant difference in other autoimmune disorder (Li, Zhao 
et al. 2011). Thus, FoxP3 is a candidate gene for its functional importance in the development 
of autoimmune disease. Another candidate gene for autoimmune disease is AIRE 
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(autoimmune regulator). This is a transcription factor is involved in central tolerance and 
clonal deletion of self-reactive T-cells. DNA methylation in CpG sites of the AIRE promoter 
controls its tissue specific expression (Kont, Murumagi et al. 2011). For an instance, DNA 
methylation of histone 3 affects the expression of AIRE (Javierre, Esteller et al. 2008).  
 
There are several methods to analyze DNA methylation status. Bisulfite conversion followed 
by PCR and sequencing (BSP) is one the mostly used method, and often called the gold 
standard in monitoring DNA methylation as it allows for single-base pair resolution maps. 
Sodium bisulfite, which is a mutagen in the environment, leads to determination of cytosine 
into uracil. The major advantages of the bisulfite method are accurate display of 5-
methylcytosine and the capacity to generate sequence data for individual CpG sites and DNA 
strands (Frommer, McDonald et al. 1992). The established BSP protocol in Marit Bakke lab 
uses nested PCR instead of traditional PCR after bisulfite conversion because the bisulfite 
treated DNA is fragile and difficult to amplify. Nested PCR enable us to amplify the region of 
interest without requiring too much template and reduce nonspecific amplification. BSP was 
used initially in this master thesis to assess DNA methylation differences between AAD 
patients compared to control blood donors across one genomic region that were identified in 
the MeDIP-chip as differentially methylated in patients and controls (data not shown). The 
gene analyzed with this method was FoxP3, as AAD patients where hypermethylated 
compared to controls in the promoter region of this gene. The BSP analysis of FoxP3 
revealed no differences in the methylation status between patients and controls (figure_7). 
The main drawback with the BSP approach in this context is the very low throughput. Only a 
very limited amount of individuals and clones can be analyzed at a time, and thus BSP is not 
suitable as a screening method. At present, therefore, no conclusion can be drawn from the 
BSP analysis of the FoxP3 gene due to the few clones analyzed from only two individuals. 
Because of these limitations of BSP, we decided to establish MSP in the lab; partly to verify 
the MeDIP-chip results, but also to obtain a tool to screen other cohorts across interesting 
regions. 
 
MSP is a method in which the amplification of a genomic region depends on the methylation 
status of the sequence covered by the primers (Rand, Qu et al. 2002). MSP is probably most 
sensitive non-quantitative method due to its capability to detect 0.1% methylation or less 
which can cover any block of CpG sites (Rand, Qu et al. 2002; Kristensen, Mikeska et al. 
2008). This method can be made quantitative by either labeling the primers with fluorofores 
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or by combining the MSP primers with an internal labeled fluorescent probe. The quantitative 
version of MSP is also known as MethyLight, and allows for moderate-throughput 
quantitative methylation profiling of a group of gene (Zuo, Tycko et al. 2009). The main 
drawback of MSP is that it can be very challenging to design primer sets that will work well 
for both unmethylated and methylated sites. The software Methyl Express was used to design 
the primers, but still this part is very time consuming. Many primer sets were evaluated in 
silico, and for most genes several sets of primers were also tested in the lab. It was observed 
that the software often recommended an annealing temperature 3-5ºC higher that what was 
found to be optimal for the PCR. My observations also suggested that the unmethylated 
primer pairs worked better at higher melting temperatures than the methylated primer pairs, 
and different annealing temperature were therefore often used for the methyalated and 
unmethylated primers for a specific region. Another problem with all bisulfite-based methods 
is incomplete conversion unmethylated cytosine to uracil. This fact may lead to that the 
primer sets do not hybridize well to the region of interest and inhibit specific primer binding. 
To overcome this challenge with MSP, controls in the form of completely methylated and 
unmethylated DNA are necessary. Completely methylated control DNA is available 
commercially, but the completely unmethylated control DNA purchased from New England 
Biolabs was not reliable. Demethylated DNA was therefore prepared by whole genome 
amplification (WGA) of DNA isolated from whole blood. In WGA the DNA is amplified 
without any addition of the methyl group to the newly formed DNA molecules due to lack of 
DNMTs and the methyl source s-adenosyl methionine (SAM) in the reaction. (Kristensen, 
Mikeska et al. 2008).  
Though MSP is a highly sensitive and virtually capable to recognize any block of 
differentially methylated CpG sites (Umetani, de Maat et al. 2005), it need optimization of 
temperature and cycle alongside proper methylated and unmethylated control DNA. The 
temperature when preparing the MSP samples is critical, and if the sample with both template 
and polymerase is stored at room temperature GoTaq polymerases could facilitate 3’ 
mismatch. The samples should therefore at all times be handled on ice during preparation. 
This is especially important because bisulfite converted DNA is the template, due to higher 
chance of default template-DNA binding and primer-dimer formation. The choice of DNA 
polymerase enzyme and optimization of its activation temperature are thus a most critical step 
to successful MSP. The use of hot start DNA polymerase or DNA polymerase addition after 
initiation step could be ways to overcome this critical situation. Inappropriate melting 
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temperature can cause primer binding to wrong places and this can give a smear in the 
agarose gel. A second step that should be optimized is the DNA concentration used in the 
reaction. DNA concentration should be fixed for both positive and negative control DNA  
(methylated and unmethylated DNA, respectively) as well as the patient/control sample 
during the primer screening. 
 
MeDIP and subsequent hybridization to DNA tilling arrays, followed by statistical analyses 
identified genomic regions that where differently methylated in all patients compared to all 
controls (appendix 1 page 68-70). In characterization of genes related to autoimmune disease 
it is not essential that the genes are “ immune response” gene. It is established Chen et al. that 
the genes also could be involved in apoptosis, cell cycle progression, cell differentiation and 
migration (Maas, Chan et al. 2002). The criteria mentioned in the results section were used as 
basis to select genes for MSP analysis. The following genes were selected because of their 
relation to autoimmune diseases along with their interesting DNA methylation pattern and 
their possible connection in AAD. 
 
FLCN (coding for protein folliculin): The protein is characterized as a possible tumor 
suppressor involved in apoptosis by two different signalling pathways (Vocke, Yang et al. 
2005; Hong, Oh et al. 2010; Hudon, Sabourin et al. 2010; Cash, Gruber et al. 2011). It is 
involved in energy and/or nutrient sensing through mTOR signaling pathways (Hartman, 
Nicolas et al. 2009; Lim, Fujikane et al. 2012). This protein has not been directly linked to 
autoimmunity before, but because of the role of its interacting partner protein Bim in the 
termination of immune response it was included as a interesting gene investigate further with 
the MSP analysis. Moreover, the region identified as hypermethylated in patients was 
localized to a CGI shore, and completely covered a protein coding exon (figure_10A). CGI 
shores are of particular interest as they are often present in gene regulatory regions and are 
often differently methylated between tissues (Irizarry, Ladd-Acosta et al. 2009).  
 
SLC30A10 (Zn transporter): This gene is highly expressed in the liver and has an important 
function in zinc and manganese transport. Mutations in this gene are recognized in 
autoimmune Parkinson’s disease development (Hamza, Zabetian et al. 2010; Tuschl, Clayton 
et al. 2012). The gene-encoded protein, which is belongs to large family of membrane 
transporters is involved in effluxion of divalent cations from the cytosol. Depletion of 
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SLC3OA10 in liver is responsible for the development of autoimmune Parkinson’s disease 
(Quadri, Federico et al. 2012).  
 
HDAC4 (Histone deacetylase 4): The involvement of HDACs in autoimmunity is well 
established where inhibition of histone deactylase can increase FoxP3 expression and 
suppressive function of TREG cells (Tao, de Zoeten et al. 2007). HDAC4 is expressed in a 
tissue-specific pattern and mainly expressed in TREG cells (Lal and Bromberg 2009). This gene 
interacts with and repress MADS-box MEF2 transcription factor and therefore also repress T-
cells stimulation (Potthoff and Olson 2007). MEF2 is a transcription factor involved in 
multiple signalling pathways and is also required for B-cells proliferation (Wilker, Kohyama 
et al. 2008). The covering area (second but first protein coding exon) has a high density of 
CpG sites and altogether this indicated the possibility of transcriptional regulation by DNA 
methylation.   
 
RCC2 (regulator of chromosome condensation 2): This protein is required completion of 
mitosis and cytokinesis. It may also function as a guanine nucleotide exchange factor for the 
small GTPase RAC1 (Grigera, Ma et al. 2012). Though the gene has not been reported to be 
involved in the development of autoimmunity, the methylation pattern identified and the 
amount of hits in the array made this gene potentially interesting. The hypothesized role of 
DNA methylation in the gene might be linked to, inhibition of mitosis and cytokinesis. 
 
GRIN2B (N-methyl-D-aspartate receptor subunit 2B): N-methyl-D-aspartate (NMDA) 
receptors are a class of ionotropic glutamate receptors mainly known as neuropsychiatric 
factors. The genes encoding these proteins have been associated with schizophrenia, a 
pathogenic autoimmune disease (Carter 2011). GRIN2B is a part of a NMDA receptor 
channel which has been shown to be involved in long-term potentiating, an activity-dependent 
increase in the efficiency of synaptic transmission thought to underline certain kinds of 
memory and learning (Dorval, Wigg et al. 2007). Interestingly, the only CpG-island present in 
this gene, fully covers the region that was identified as hypermethylated in controls. This 
information insinuates that transcriptional regulation of the gene could be governed by DNA 
methylation.  
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Due to time limitations, MSP was only carried out across FLCN on patient DNA. As 
mentioned above it became evident after this analysis (figure_15) that even though MSP can 
clearly distinguish between completely methylated or unmethylated DNA, this method is 
probably not sensitive enough to discriminate between individuals with less robust differences 
in methylation status. Q-MSP, or MethyLight as described above, will most likely be required 
to determine the methylation differences between patients and controls across the different 
genomic regions. However, the MSP-results presented in figure_15, still indicates the same 
results as the array, namely that the identified region in FLCN is hypermethylated in AAD 
patients compared to controls. It is expected that this would lead to decreased FLCN 
expression in AAD patients, but this remains to be tested experimentally. The skin 
pigmentation observed in AAD patients develops as a consequense of interuption of feedback 
inhibition from the adrenal and the hypothalamus and anterior pituitary gland. The 
disturbance leads to melanogenesis by melanocyte stimulating hormone secretion coupled 
with corticotropin (Burk, Ciocca et al. 2008) (figure_16A). Interestingly, the potential 
repressed expression of FLCN in AAD patients indicate a possible alternative mechanism for 
pigmentation in AAD patients (figure_16). This hypothetical model suggests that under 
expression of FLCN due to increased DNA methylation, a factor called of TFE3 will be 
induced (Hong, Oh et al. 2010). Induction of TFE3 overexpression stimulates lysosomal 
biogenesis. Thereon, an increased level of lysosomal biogenesis adds up to melanosome 
biogenesis and causes pigmentation in different organs. It should be mentioned that TFE3 is 
one among four members of the MiT/TFE transcription factor subfamily that is important for 
the expression of genes that encode lysosomal proteins such as melanin (Sardiello, Palmieri et 
al. 2009).   
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Figure_16: Proposed mechanism of hypermethylated FLCN gene in clinical manifestation by 
producing pigmentation for AAD patients. A: The established pathway leading to 
hyperpigmentation of AAD patients (Burk, Ciocca et al. 2008). B: A hypothetical alternative 
pathway for hyperpigmentation in AAD patients involving FLCN and TFE3. 
 
Another interesting link between FLCN and AAD is proposed based on the direct 
involvement of FLCN gene on the development of autoimmunity by apoptosis (figure_17). 
An important regulator of apoptosis is the pro-apoptotic gene BH3-only pro-apoptotic Bcl-2 
family member, commonly known as Bim. It is reported that FLCN gene expression can 
affect on Bim expression in the TGF-ß signalling pathway (Hong, Oh et al. 2010). The 
association between FLCN and Bim, as well as the individual function of Bim in apoptosis is 
regulated by FLCN expression via a positive feedback mechanism (Hong, Oh et al. 2010). 
The role of Bim in termination of immune response is to repress activated T-cells, as 
demonstrated in several studies (Pellegrini, Belz et al. 2003). The termination process requires 
Bim for the death of activated T-cells by apoptosis (Bouillet, Purton et al. 2002). FNIPL 
(Folliculin Interacting Protein 1-like) and FNIP2 (Folliculin Interacting Protein 2) are 
reported as interacting partners of FLCN (Hasumi, Baba et al. 2008). FNIP2 and FNIPL, as 
well as FNIP1 (Folliculin Interacting Protein 1) can interact with AMPK (5' AMP-Activated 
Protein Kinase) (Hardie 2004). Through the AMPK signalling pathway, a complex composed 
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of MAPO1 (O(6)-methylguanine-Induced Apoptosis 1), FLCN and AMPK is involved in the 
induction of apoptosis (Lim, Fujikane et al. 2012). On the other hand, the gene has a potential 
function in reducing nutrient supply for cell growth and survival maintained by mTOR 
signalling, leading to apoptosis (Hartman, Nicolas et al. 2009) (figure_17A), and might be the 
nutrient supplier for auto reactive T-cells populations in AAD patients (figure_17B). When it 
comes to Bim function in apoptosis and termination of immune response, the proposed 
hypothesis is presented in figure_17 the diagram below where the function of 
hypermethylated FLCN have described in the development of autoimmunity (figure_17B). 
Overall, the hypothesis annotated the FLCN gene in the development of autoimmunity of 
AAD patients due to lack of apoptosis of negatively selected auto reactive T-cells. 
 
Figure_17: Proposed hypothesis of FLCN gene function in autoimmunity.  
 
A: FLCN gene function in apoptosis through three different signalling processes; AMPK signalling, 
Akt signalling and TGF-ß signalling pathway might be involved in elimination process of auto 
reactive T-cells from both systemic and organ specific autoimmune patients. B: Impair FLCN 
expression no longer be able to eliminate T-cells by apoptosis, which are selected by negative 
selection and developing autoimmunity.  
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Taken together, the results presented in this thesis contribute to the development of a MSP 
based screening approach to analyze genomic regions that are differentially methylated in 
patients with AAD. As it is possible to analyze relatively many samples at the same time, the 
goal is that large cohorts of both AAD patients and patients with other autoimmune diseases 
can be screened. Such studies will contribute to our understanding of the epigenetic signatures 
of different cohorts, and will also possibly reveal epigenetics similarities or dissimilarities 
between groups suffering from different autoimmune diseases. However, although more 
genomic regions should be analyzed before concluding, the results obtained on FLCN indicate 
that it will be necessary to develop qMSP to differentiate between hyper and hypomethylated 
regions. Future experiments will also focus on the relative functional consequences of an 
aberrant methylation pattern, i.e. it will be determined how overexpression or reprssion of a 
specific protein will affect T-cells differentiation, proliferation and immune responsiveness 
among other parameters. Such information is essential with the ultimate in mind; to develop 
novel therapeutic strategies or biomarkers. Because although most AAD patients in Norway 
live relatively normal lives after steroid hormone therapy, world wide, autoimmune diseases 
is a major cause of suffering, illness and death.  
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Appendix I 
 
1.6.3 Methylated DNA immunoprecipitation microarray (MeDIP-chip) 
 
 Methylated DNA Immunoprecipitation (MeDIP) is a genome-wide, high-resolution approach 
to detect differently methylated genomic regions in DNA samples. The method was 
developed by Weber et al (Weber, Davies et al. 2005), and can be combined with large-scale 
analysis. The basic principle is the enrichment of methylated DNA with an antibody that 
specifically binds to 5mC after sonication of purified genomic DNA (Palmke, Santacruz et al. 
2011). The enriched methylated DNA then can be combined DNA microarrays (MeDIP-chip) 
or high throughput sequencing (MeDIP-seq). MeDIP is also suitable for allele-specific studies 
by combining it with PCR. Though MeDIP is a relatively efficient method to detect 
methylated DNA, the denaturation step can make the genomic DNA fragile or degraded and 
low quality DNA will remain for subsequent studies. Antibody specificity can also be 
problem, but all of these obstacles are greatly reduced in the MeDIP kits that are now 
available. Moreover, DNA sonication instead of denaturation in the initial step enhances the 
protocol. Methylated DNA-Binding protein (MBDCap) can be used as an alternative to 
antibodies against 5mC. Both antibodies will precipitate methylated DNA and are suitable for 
detecting DMRs (Differentially Methylated Region). MBDCap works better for genomic 
regions with higher CpG density, which was not a requirement for our experimental design. 
MBDCap also requires more DNA, and the protocol is more cumbersome (Nair, Coolen et al. 
2011). The overall workflow of MeDIP-chip is presented in figure_18.  
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Figure_18: Workflow of the methylated DNA immunoprecipitation microarray (MeDIP-
chip). Desired fragments length was generated by sonication and incubated with an antibody 
directed against 5mC and methylated DNA is isolated by immunoprecipitation. Whole 
genome amplification was introduced to get sufficient amount of DNA for quantification the 
methylated fractions by comparing with two-colour experiment in microarray analysis. 
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MeDIP-chip is a microarray-based genomic survey used in DNA methylation analysis 
because of its high throughput manner. The method has successfully been applied both in 
animals and plants to identify differences in DNA methylation (Weng, Huang et al. 2009). 
Relatively large amounts of DNA are required for array hybridization, but the outcome from 
the MeDIP is usually in 50-100 ng in range. To obtain enough DNA, whole genome 
amplification (WGA) was performed before microarray to increase the copy number of 
enriched genomic sequences (Weber, Davies et al. 2005). It is critical that all loci are 
amplified equally to ensure unbiased hybridization to the array. WGA also simplifies the 
analysis of DNA from tissues that are limited, but “false positive” results for some specific 
regions might be experienced as a limitation for MeDIP-chip (Jia, Pekowska et al. 2010). A 
potential limitation of MeDIP is also the fact that large genomic regions with a high CpG 
content will be more efficient precipitated than a region with few CpG sites. Depending on 
the purpose of the study this might be a limitation, and moreover as a result of this bias, 
validated sequences could be just opposite in methylation status to the same genomic region 
of methylated DNA. Genomic DNA is sheared to low molecular weight fragment after 
sonication, with an average size of 400 bp. Therefore, this is not disadvantage of the method 
but need to simplify. Other than this particular condition, MeDIP-chip is adequate for DNA 
methylation analysis. Thereafter, multiple accessibility for data validation inspired to chose 
the method as well.  
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Appendix II 
 
The region obtained from the result of Human DNA Methylation 2.1M Delux Promoter array 
analysis is corresponding to the gene and gene description listed here according to UCSC 
genome browser (http://genome.ucsc.edu/); in the first column, chromosomal location of each 
gene have mentioned. The mean in the second column describes the score of relative 
methylation in this region. The value over two is defined as significantly methylated. This 
score is the case group and all controls has scored below two in this region meaning that the 
controls are not methylated.  
Table_XXII: List of genes from MeDIP-chip result 
 
